<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4161047</article-id><article-id pub-id-type="doi">10.3389/fimmu.2014.00431</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Type I Interferons in Bacterial Infections: Taming of Myeloid Cells and Possible Implications for Autoimmunity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eshleman</surname><given-names>Emily M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/148044"/></contrib><contrib contrib-type="author"><name><surname>Lenz</surname><given-names>Laurel L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/25715"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Immunology and Microbiology, University of Colorado School of Medicine</institution>, <addr-line>Aurora, CO</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biomedical Research, National Jewish Health</institution>, <addr-line>Denver, CO</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Yoichi Furuya, Albany Medical College, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Birgit Strobl, University of Veterinary Medicine Vienna, Austria; Yubin Zhang, Fudan University, China</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Laurel L. Lenz, Department of Immunology and Microbiology, University of Colorado School of Medicine, Mail Stop 8333, Room P18-9130, 12800 E. 19th Avenue, Aurora, CO 80045-2537, USA e-mail: <email>laurel.lenz@ucdenver.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology.</p></fn></author-notes><pub-date pub-type="epreprint"><day>03</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>11</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>5</volume><elocation-id>431</elocation-id><history><date date-type="received"><day>19</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Eshleman and Lenz.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Type I interferons (IFNs) were first described for their ability to protect the host from viral infections and may also have beneficial effects under specific conditions within some bacterial infections. Yet, these pleiotropic cytokines are now known to exacerbate infections by numerous life-threatening bacteria, including the intracellular pathogens <italic>Listeria monocytogenes</italic> and <italic>Mycobacterium tuberculosis</italic>. The evidence that such detrimental effects occur during bacterial infections in both animals and humans argues for selective pressure. In this review, we summarize the evidence demonstrating a pro-bacterial role for type I IFNs and discuss possible mechanisms that have been proposed to explain such effects. The theme emerges that type I IFNs act to suppress myeloid cell immune responses. The evolutionary conservation of such anti-inflammatory effects, particularly in the context of infections, suggests they may be important for limiting chronic inflammation. Given the effectiveness of type I IFNs in treatment of certain autoimmune diseases, their production may also act to raise the threshold for activation of immune responses to self-antigens.</p></abstract><kwd-group><kwd>interferons</kwd><kwd>interferon receptors</kwd><kwd>bacterial pathogens</kwd><kwd>macrophage activation</kwd><kwd>immune suppression</kwd><kwd>autoimmunity</kwd></kwd-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="137"/><page-count count="11"/><word-count count="10503"/></counts></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p>Type I interferons (IFNs) are a class of cytokines that includes numerous IFN&#x003b1; subtypes, IFN&#x003b2;, IFN&#x003b4;, IFN&#x003b5;, IFN&#x003ba;, IFN&#x003c4;, and IFN&#x003c9; (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). These secreted factors are predominantly produced by innate immune and non-immune cells of humans and other animals in response to recognition of conserved microbial products, rather than specific antigens. The different type I IFNs vary in their sequences but bind and signal using a common, ubiquitously expressed, heteromeric cell surface receptor (IFNAR) comprised of IFNAR1 and IFNAR2 chains. Ligation of IFNAR in diverse cell types activates a canonical JAK/STAT signaling cascade primarily involving JAK1, Tyk2, STAT1, and STAT2 proteins. Activation of these factors leads to induced transcription of numerous type I IFN-stimulated genes (ISGs), the protein products of which largely act to disrupt various stages of viral replication (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Type I IFNs are thus important for resistance to several viral infections and are used in the clinic for effective antiviral therapy (<xref rid="B2" ref-type="bibr">2</xref>). However, type I IFNs also exert a variety of other effects on cellular functions and immune responses. For example, they up or down regulate production of and responsiveness to other cytokines, chemokines, and can stimulate cell growth, cell survival, or apoptosis (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Consequently, these cytokines are also used for treatment of melanomas, leukemias, and other cancers (<xref rid="B6" ref-type="bibr">6</xref>), and as immune modulatory agents to suppress neuroinflammation in patients suffering from relapse-remitting multiple sclerosis (MS) (<xref rid="B2" ref-type="bibr">2</xref>). Hence, type I IFNs exert seemingly opposing pro- or anti-inflammatory effects and pro- or anti-apoptotic effects. It is likely that these opposing effects reflect cell type-specific differences in the activation of secondary or &#x0201c;non-canonical&#x0201d; signaling events and/or variations in the dominance of a specific type I IFN species. Indeed, individual type I IFN proteins vary in their ability to elicit specific responses and stimulation of different cell types can cause distinct signaling events (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p><p>The second class of IFN protein (type II or IFN&#x003b3;) is more critical for host defense against intracellular bacterial pathogens, such as <italic>Mycobacterium tuberculosis</italic> and <italic>Listeria monocytogenes</italic>. IFN&#x003b3; signals through its own ubiquitously expressed heteromeric receptor (IFNGR), which utilizes IFNGR1 and IFNGR2 chains to activate a canonical JAK/STAT pathway primarily involving JAK1, JAK2, and STAT1. In contrast to type I IFNs, which are broadly expressed, IFN&#x003b3; is produced primarily by lymphocytes. Antigen-specific IFN&#x003b3; production occurs when appropriate T lymphocyte populations respond to specific microbial antigens, while antigen non-specific production of IFN&#x003b3; is stimulated by cytokines such as interleukin (IL)-12 and IL-18. Studies using <italic>L. monocytogenes</italic> and other bacterial infection models indicate that both T and natural killer (NK) cells are capable of this antigen non-specific IFN&#x003b3; production (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). Myeloid cells such as macrophages and dendritic cells (DCs) are key targets of IFN&#x003b3;, as shown by the increased susceptibility to <italic>L. monocytogenes</italic> infection in mice selectively defective for functional IFNGR1 in myeloid cells (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). The expression of numerous IFN&#x003b3; activated genes (GAGs) is induced by the cytokine. Some of these genes are identical to ISGs and have antiviral effects. However, IFN&#x003b3; is unique in its ability to elicit a potent anti-microbial state of activation in macrophages. This &#x0201c;M1-type&#x0201d; activation is associated with increased expression of GAGs such as nitric oxide synthase 2 (NOS2) and NADPH oxidase subunits. These enzymes generate nitric oxide (NO) and reactive oxygen species (ROS) that alter cell signaling and under appropriate circumstances can mediate direct killing of bacteria (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). IFN&#x003b3;-inducible GTPases also promote macrophage resistance to bacterial and parasite infections by increasing the ability of phagosomal compartments to contain and kill engulfed microbes (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). IFN&#x003b3; also upregulates myeloid cell expression of MHC II and other factors important for antigen presentation and T cell activation (<xref rid="B19" ref-type="bibr">19</xref>). In addition, IFN&#x003b3; impacts maintenance and proliferation of hematopoietic stem cells (HSC). Specifically, basal production of IFN&#x003b3; in the absence of infection drives HSC cycling and the elevated levels occurring during infection can activate HSC proliferation and myelopoiesis to replenish monocytes and other immune cells (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p><p>Despite the antiviral effects of type I IFNs, and in the context of the antibacterial effects of IFN&#x003b3;, it is increasingly evident that host responsiveness to type I IFNs correlates with increased host susceptibility to infections by <italic>L. monocytogenes</italic>, <italic>M. tuberculosis</italic>, <italic>Francisella tularensis</italic>, and several other intracellular bacterial pathogens (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>). Here, relying heavily on the <italic>L. monocytogenes</italic> model, we review the pathways involved in the induction of type I IFNs by intracellular bacteria and various mechanisms proposed to account for the suppressive effects of type I IFN signaling. A theme that emerges from these studies is that type I IFNs have suppressive effects on anti-microbial and antigen-presenting function of myeloid cells. Such effects may contribute to both the observed ability of these cytokines to increase host susceptibility during bacterial infections and to their effectiveness in therapy of neuroinflammatory disease.</p></sec><sec id="S2"><title>Bacterial Factors Contributing to Type I IFN Production during <italic>L. monocytogenes</italic> Infection</title><p><italic>Listeria monocytogenes</italic> is a Gram-positive facultative intracellular bacterium that causes the systemic disease Listeriosis. The mortality rate of Listeriosis is quite high even in hospitalized patients; hence, <italic>L. monocytogenes</italic> remains a leading cause of death from foodborne illnesses within the United States. <italic>L. monocytogenes</italic> can infect hematopoietic and non-hematopoietic cell types through phagocytosis or cellular mediated uptake (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Following systemic infection in the murine model <italic>L. monocytogenes</italic> localizes to the liver and spleen where resident phagocytes, primarily macrophages and DCs, engulf the bacteria. <italic>L. monocytogenes</italic> that escape from phagosomal compartments in these cells can replicate within the cell cytosol and further propagate the infection into neighboring cells. To facilitate vacuolar escape, the bacteria secrete a pore-forming hemolysin (hly) known as listeriolysin O (LLO) (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>Like many other bacteria, <italic>L. monocytogenes</italic> induces production of pro-inflammatory cytokines such as TNF&#x003b1; and type I IFNs when engulfed by professional phagocytes. Studies of infection in bone marrow derived macrophages (BMM) suggest that there are two waves of the cellular response to <italic>L. monocytogenes</italic> infection (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). An &#x0201c;early phase&#x0201d; gene expression profile is seen at 1&#x02013;2&#x02009;h post infection by both virulent wild-type <italic>L. monocytogenes</italic> and avirulent &#x00394;hly or heat-killed bacteria that cannot escape from vacuolar compartments into the host cytosol (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Several of these &#x0201c;early phase&#x0201d; genes, including <italic>il1b</italic>, <italic>tnfa</italic>, and those encoding several chemokines are induced through the activation of Toll-like receptor (TLRs) and the ensuing activation of NF&#x003ba;B (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). A subsequent &#x0201c;late-phase&#x0201d; response is observed at 4&#x02013;8&#x02009;h after infection by wild-type, but not killed or &#x00394;hly, <italic>L. monocytogenes</italic> strains (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). &#x0201c;Late-phase&#x0201d; genes include IFN&#x003b2;, multiple subtypes of IFN&#x003b1;, and several ISGs (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). The fact that killed and &#x00394;hly <italic>L. monocytogenes</italic> strains fail to induce this late-phase IFN-dominated response supports the interpretation that products from bacteria replicating within the BMM cytosol stimulate cytosolic pathogen recognition receptors (PRR), though TLR stimulation can augment the induction of type I IFNs during <italic>L. monocytogenes</italic> infection (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). There has been considerable interest in identifying the cytosolic PRRs responsible for type I IFN production during <italic>L. monocytogenes</italic> infection.</p></sec><sec id="S3"><title>Pathways Leading to the Production of Type I IFNs during Bacterial Infection</title><p>Pathways known to be important for induction of type I IFN within <italic>L. monocytogenes</italic>-infected phagocytes are diagrammed in Figure <xref ref-type="fig" rid="F1">1</xref>. Amongst the earliest identified cytosolic PRRs were the nucleotide-binding oligomerization domain (NOD)-containing proteins; members of the nucleotide-binding domain, leucine-rich repeat (LRR) protein family referred to as NLRs. NOD1 and NOD2 proteins sense distinct muropeptide fragments from the cell wall from <italic>L. monocytogenes</italic> and other bacteria (<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>). Recognition of appropriate muropeptides activates a serine/threonine kinase receptor interacting protein (RIP2) to initiate downstream signaling and activation of NF&#x003ba;B (<xref rid="B31" ref-type="bibr">31</xref>). With regards to triggering of type I IFN production, NOD1, NOD2, and RIP2 seem to play an ancillary role. They augment the induction of type I IFN and other cytokine expression in response to <italic>L. monocytogenes</italic> (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>), but mice and BMM deficient for any one of these proteins retain the ability to mount inflammatory responses and synthesize type I IFNs in response to <italic>L. monocytogenes</italic> (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Thus, the recognition of bacterial cell wall components by the cytosolic NOD1 and NOD2 proteins is not crucial for the induction of type I IFNs during <italic>L. monocytogenes</italic> infection.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Pathways implicated in type I IFN production following <italic>L. monocytogenes</italic> infection</bold>. Several cytosolic receptors are able to recognize <italic>L. monocytogenes</italic> (Lm) microbial components to induce type I IFN production. (Yellow) Endosomal TLRs recognize a variety of Lm bacterial patterns including cell wall fragments, which can also stimulate NOD proteins. NOD proteins require association with RIP2 to activate TBK1. Lm secretes RNA, DNA, and cyclic-di-nucleotides. Secreted RNA (red) binds to RIG-I or MDA5, both of which associate with MAVS. Cytosolic DNA (blue) can alternatively be converted into RNA by RNA polymerase III and induce type I IFNs through the RIG-I pathway. DNA is also directly sensed by DDX41 or IFI16 to induce the production of type I IFNs in a STING-dependent mechanism. cGAS can sense DNA and convert it into cGAMP, which binds with high affinity to STING to stimulate IFN&#x003b2; production. C-di-nucleotides bind to STING directly and to DDX41, either of which may result in IFN&#x003b2; synthesis. TBK1 and IRF3 are essential for the induction of type I IFN production during Lm infection, and each of these upstream sensing pathways converges on TBK1 activation.</p></caption><graphic xlink:href="fimmu-05-00431-g001"/></fig><p>Nucleic acids are potent inducers of type I IFN production and it was shown that extracts from <italic>L. monocytogenes</italic> induce IFN&#x003b2; production in a manner sensitive to DNAse treatment of the extracts (<xref rid="B36" ref-type="bibr">36</xref>). <italic>L. monocytogenes</italic> was also reported to actively secrete both RNA and DNA during infection of macrophages (<xref rid="B37" ref-type="bibr">37</xref>). Cytosolic RNA is detected by the RNA helicase retinoic acid inducible gene 1 protein (RIG-I), related RIG-I-like (RLR) proteins including melanoma differentiation-associated gene 5 (MDA5), as well as other non-RLR helicases and PRRs (<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>). RNA recognition by RIG-I and MDA5 induces their recruitment to mitochondria, where they encounter an adaptor protein [mitochondrial antiviral signaling (MAVS)] that regulates downstream signaling to induce type I IFNs (<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>). Secreted <italic>L. monocytogenes</italic> DNA could also be detected using these RNA receptor systems if it is transcribed into RNA by host cell RNA polymerase III (<xref rid="B37" ref-type="bibr">37</xref>). However, deficiency in RIG-I, MDA5, or MAVS fails to ablate IFN&#x003b2; production by <italic>L. monocytogenes</italic>-infected BMM (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Thus, it does not appear that RNA sensing is crucial for recognizing cytosolic <italic>L. monocytogenes</italic> infection in this cell type, although it may play a more important role in sensing <italic>L. monocytogenes</italic> infection of other cell types and for sensing infection by other bacteria, namely <italic>Legionella pneumophila</italic> (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>).</p><p>DNA present in the host cell cytosol can also be detected and trigger the production of type I IFNs (<xref rid="B40" ref-type="bibr">40</xref>). Several putative receptors have been identified that might mediate such recognition, including the DNA-dependent activator of IRFs (DAI), IFN-inducible gene (IFI)-16, and LRR flightless-interacting protein (LRRFIP1). Deficiency or knockdown of DAI, IFI16, or LRRFIP1 fails to completely ablate type I IFN production by infected murine BMM (<xref rid="B48" ref-type="bibr">48</xref>&#x02013;<xref rid="B50" ref-type="bibr">50</xref>). However, recently IFI16 was shown to have a larger role in the recognition of <italic>L. monocytogenes</italic> DNA in the human macrophage cell line, THP1. Knockdown of IFI16 in these cells drastically reduced the production of IFN&#x003b2; in response to <italic>L. monocytogenes</italic> DNA (<xref rid="B51" ref-type="bibr">51</xref>). The DNA-binding DEAD-box helicase DDX41 has also been shown to bind <italic>L. monocytogenes</italic> DNA. DDX41 elicits type I IFN production through a mechanism requiring the stimulator of interferon genes protein (STING), also called MITA, MPYS, or ERIS (<xref rid="B52" ref-type="bibr">52</xref>). STING induces type I IFN production by activating the TNFR-associated NF-&#x003ba;B kinase (TANK)-binding kinase 1 (TBK1), which phosphorylates a C-terminal serine residue on the transcription factor IFN regulatory factor 3 (IRF3) to induce IRF3 dimerization and nuclear translocation (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B53" ref-type="bibr">53</xref>). IRF3 and other IRF family members bind to the promoters of type I IFN genes and ISGs to regulate and initiate their transcription. TBK1 and IRF3 are thus not surprisingly essential for the production of type I IFNs during <italic>L. monocytogenes</italic> infection (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B54" ref-type="bibr">54</xref>). Likewise, deficiency or knockdown of STING significantly decreases IRF3 activation and IFN&#x003b2; production in BMM, DC, or fibroblasts infected with <italic>L. monocytogenes</italic> (<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>).</p><p>It appears that STING does not respond to intact DNA, but rather to endogenous or exogenous cyclic-di-nucleotides (<xref rid="B40" ref-type="bibr">40</xref>). In the presence of cytosolic dsDNA, the enzyme cGAS synthesizes an endogenous cyclic-di-nucleotide, cGAMP (<xref rid="B58" ref-type="bibr">58</xref>). Binding of cGAMP to STING occurs with a very high affinity (~4&#x02009;nM) and induced conformational changes that presumably initiate the downstream events that culminate in type I IFN production (<xref rid="B59" ref-type="bibr">59</xref>). Exogenous cyclic-di-nucleotides can also activate STING (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Both cyclic-di-GMP (cdGMP) and cyclic-di-AMP (cdAMP) are produced by bacteria and function as second messengers. There is evidence that cdAMP is released from replicating <italic>L. monocytogenes</italic> (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>), thus it is conceivable that cdAMP secreted by the bacterium mediates the STING-dependent production of type I IFNs in <italic>L. monocytogenes</italic>-infected macrophages. However, while the affinity of cdAMP for STING is not known, STING binds cdGMP ~300-fold lower affinity (~1&#x02009;&#x003bc;M) than cGAMP DNA (<xref rid="B59" ref-type="bibr">59</xref>). Thus, it is also conceivable that cGAMP produced by cGAS in response to secreted bacterial DNA contributes to STING-dependent type I IFN production. Regardless, it is important to keep in mind that STING deficient mice showed significantly reduced serum IFN&#x003b2; only very early (8&#x02009;h) after <italic>L. monocytogenes</italic> infection (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>). Thus, systemic <italic>L. monocytogenes</italic> infection can trigger type I IFN through multiple pathways and the impact of STING on overall type I IFN production in this model is limited.</p></sec><sec id="S4"><title>Type I IFN Signaling and Increased Susceptibility to Bacterial Infection</title><p>In certain bacterial infection models, protective effects of type I IFNs have been reported. For example, type I IFN can reduce bacterial burdens in cultured cells infected with <italic>L. pneumophila</italic> or <italic>Chlamydia trachomatis</italic> and survival of mice is increased in sepsis models with group B <italic>Streptococcus</italic> and <italic>E. coli</italic> (<xref rid="B63" ref-type="bibr">63</xref>&#x02013;<xref rid="B65" ref-type="bibr">65</xref>). Mice lacking expression of IFN&#x003b5;, which is abundantly expressed within the female reproductive tract, were also reported to be highly susceptible to urogenital infection by <italic>C. muridarum</italic> (<xref rid="B66" ref-type="bibr">66</xref>). The precise mechanisms are not clear in these cases, but the observed protective effects appear to reflect unique aspects of the models and/or pathogens studied since there is considerable evidence to indicate that type I IFNs instead play a deleterious role during infections by numerous other bacterial pathogens (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>). Specifically, studies with mice lacking IFNAR1 report that bacterial burdens are significantly reduced and survival increased following systemic or mucosal infections with intracellular bacteria that infect the cytosol of host cells, such as <italic>L. monocytogenes</italic> (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B67" ref-type="bibr">67</xref>&#x02013;<xref rid="B70" ref-type="bibr">70</xref>) and <italic>F. tularensis</italic> (<xref rid="B71" ref-type="bibr">71</xref>) as well as bacteria like <italic>M. tuberculosis</italic> (<xref rid="B72" ref-type="bibr">72</xref>&#x02013;<xref rid="B74" ref-type="bibr">74</xref>) and <italic>C. muridarum</italic> (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>) that reside within vacuolar compartments. In addition, heightened type I IFN production correlates with increased host susceptibility to several bacterial infections. In mice, examples of this include the correlation of increased type I IFN production in mice with a mutated ubiquitin specific peptidase (USP18) and sensitivity to <italic>Salmonella typhimurium</italic> (<xref rid="B77" ref-type="bibr">77</xref>). Furthermore, isolates of <italic>L. monocytogenes</italic> and <italic>M. tuberculosis</italic> that hyper-induce type I IFN production have heightened pathogenicity in animal models (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>). The administration of type I IFNs or agents that induce these cytokines also causes increased susceptibility to <italic>L. monocytogenes</italic> and <italic>M. tuberculosis</italic> in model infections (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Type I IFN production is also increased during viral infections. In mice, lymphocytic choriomeningitis virus (LCMV) infection potently induces type I IFNs and leads to ~1000-fold increased susceptibility to a secondary <italic>L. monocytogenes</italic> infection as measured by bacterial burdens (<xref rid="B81" ref-type="bibr">81</xref>). In humans, a similar situation occurs following infection with influenza virus. Influenza infections are often associated with secondary bacterial infections and secondary bacterial pneumonias are estimated to account for up to 25% of the more than 250,000 annual deaths attributed to influenza (<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Such secondary infections are also thought to have caused most of the deaths from the 1918 influenza pandemic (<xref rid="B84" ref-type="bibr">84</xref>). <italic>Streptococcus pneumoniae</italic> is a prevalent bacterial cause of pneumonias and a model of influenza and secondary <italic>S. pneumoniae</italic> infection showed that increased bacterial burdens and mortality was dependent on IFNAR expression (<xref rid="B85" ref-type="bibr">85</xref>). Severe bacterial infections have also been noted in patients receiving prolonged IFN&#x003b1;2 therapy for chronic hepatitis C virus infection (<xref rid="B86" ref-type="bibr">86</xref>&#x02013;<xref rid="B88" ref-type="bibr">88</xref>). Moreover, in the absence of obvious viral infections, signatures of type I IFN responses correlate with disease progression in human tuberculosis and leprosy patients (<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>). Thus, despite numerous differences in the receptors and cytokines themselves, the association of type I IFNs with exacerbated bacterial infections appears to have been conserved in murine and human systems. An improved understanding how these cytokine responses are deleterious to their hosts and what has driven their conservation across this evolutionary span are important questions to address.</p></sec><sec id="S5"><title>Mechanisms Proposed to Account for the Pro-Bacterial Effects of Type I IFNs</title><p>A summary of the proposed mechanisms for the deleterious effects of type I IFN signaling during bacterial infections is outlined in Figure <xref ref-type="fig" rid="F2">2</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Some mechanisms previously proposed to account for the pro-bacterial effects of type I IFNs</bold>. <bold>(A)</bold> Type I IFNs up regulate pro-apoptotic genes resulting in lymphocyte (green) apoptosis. Apoptotic lymphocytes stimulate myeloid cell IL-10 secretion. <bold>(B)</bold> Increased apoptosis of myeloid cells (orange) leads to reduced amounts of inflammatory monocytes during infection. <bold>(C)</bold> Signaling through the IFNAR suppresses myeloid cell secretion of pro-inflammatory cytokines and chemokines, which can result in decreased IFN&#x003b3; production. <bold>(D)</bold> Expression of IFNGR is suppressed in response to type I IFN signaling in myeloid cells thus decreasing cellular responsiveness to IFN&#x003b3;. <bold>(E)</bold> Type I IFNs induce the production of IL-10 to inhibit IFN&#x003b3; responsiveness.</p></caption><graphic xlink:href="fimmu-05-00431-g002"/></fig><sec id="S5-1"><title>Induction of host cell death</title><p>It has long been known that bacterial infections can induce death of multiple cell types within tissues of murine hosts. In the systemic <italic>L. monocytogenes</italic> infection model, this cell death is exacerbated by type I IFNs. O&#x02019;Connell et al. observed that expression of pro-apoptotic genes such as TNF-related apoptosis-inducing ligand (TRAIL), promyelocytic leukemia (PML), and death-associated protein 6 (Daxx) were increased in the spleens of <italic>L. monocytogenes</italic>-infected wild-type, but not IFNAR1 deficient, mice (<xref rid="B54" ref-type="bibr">54</xref>). Consistent with increased apoptosis in these tissues, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining is also increased in the spleens of infected wild-type mice, when compared to infected IFNAR1<sup>&#x02212;/&#x02212;</sup> or IRF3<sup>&#x02212;/&#x02212;</sup> mice (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B69" ref-type="bibr">69</xref>). This TUNEL staining was localized to lymphocyte rich follicles within the spleens, suggesting that type I IFN might induce apoptosis of lymphocytes and that such apoptosis could itself be detrimental (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B69" ref-type="bibr">69</xref>). The possibility that lymphocyte apoptosis is deleterious to the host is also consistent with the observation that mice deficient in lymphocytes or T cells alone are resistant to acute systemic <italic>L. monocytogenes</italic> infection (<xref rid="B91" ref-type="bibr">91</xref>&#x02013;<xref rid="B93" ref-type="bibr">93</xref>). Resistance in T cell-deficient hosts is thought to reflect constitutively heightened macrophage activation (<xref rid="B94" ref-type="bibr">94</xref>), and correlates with reduced production of the anti-inflammatory cytokine IL-10 (<xref rid="B91" ref-type="bibr">91</xref>). It was thus proposed that in mice responsive to type I IFNs, the uptake of apoptotic cells by macrophages triggers their production of IL-10, which in turn inhibits host resistance (<xref rid="B91" ref-type="bibr">91</xref>). Myeloid cells are also sensitive to apoptosis in response to type I IFN and IFNAR expression has also been correlated with increased apoptosis of splenic and pulmonary macrophages during <italic>L. monocytogenes</italic> and pulmonary <italic>C</italic>. <italic>muridarum</italic> infections, respectively (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B76" ref-type="bibr">76</xref>). As mentioned above, these type I IFNs increase expression of the pro-apoptotic factor TRAIL during <italic>L. monocytogenes</italic> infection (<xref rid="B54" ref-type="bibr">54</xref>). Similar to IFNAR1<sup>&#x02212;/&#x02212;</sup> mice, mice lacking TRAIL demonstrate reduced TUNEL staining and increased resistance during <italic>L. monocytogenes</italic> infection (<xref rid="B95" ref-type="bibr">95</xref>). These effects were further correlated with increased numbers of splenic lymphocytes and monocytes. Type I IFN production induced by LCMV infection also correlates with granulocyte apoptosis and impaired control of <italic>L. monocytogenes</italic> infection (<xref rid="B81" ref-type="bibr">81</xref>). Thus, there is a clear association between type I IFNs, cellular death, and impaired myeloid cell responses during bacterial infections. Nonetheless, it remains unclear whether apoptosis of T or myeloid cells is a primary cause of the increased host susceptibility.</p></sec><sec id="S5-2"><title>Suppression of pro-inflammatory cytokine and chemokine production</title><p>Type I IFN production during viral infection is known to suppress production of IL-12 and other pro-inflammatory cytokines (<xref rid="B96" ref-type="bibr">96</xref>). Similarly, type I IFN production was associated with reduced secretion of IL-12 and TNF&#x003b1; in both <italic>L. monocytogenes</italic> and <italic>M. tuberculosis</italic> infection models (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B72" ref-type="bibr">72</xref>). Type I IFNs also suppress IL-1&#x003b2; production by inhibiting inflammasome activation (<xref rid="B97" ref-type="bibr">97</xref>), and reduced IL-1&#x003b2; secretion correlated with increased host susceptibility in <italic>M. tuberculosis</italic> infection models (<xref rid="B98" ref-type="bibr">98</xref>, <xref rid="B99" ref-type="bibr">99</xref>). Expression of chemokines such as CCL2 is also regulated by type I IFNs (<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B101" ref-type="bibr">101</xref>). CCL2 and its chemokine receptor CCR2 are critical for migration of inflammatory monocytes to sites of infection by <italic>L. monocytogenes</italic> and other bacteria (<xref rid="B102" ref-type="bibr">102</xref>&#x02013;<xref rid="B104" ref-type="bibr">104</xref>). Spleens of IFNAR1<sup>&#x02212;/&#x02212;</sup> mice have increased accumulation of inflammatory monocytes during <italic>L. monocytogenes</italic> infection (<xref rid="B68" ref-type="bibr">68</xref>), however, type I IFNs upregulate CCL2 and recruitment of monocytes into the lung during <italic>M. tuberculosis</italic> infection (<xref rid="B80" ref-type="bibr">80</xref>). In the latter study, accumulation of monocytes correlated with more severe infection. By contrast, type I IFNs were reported to impair production of CXCL1, CXCL2, and neutrophil accumulation in lungs and more severe infection in mice infected with <italic>S. pneumoniae</italic> (<xref rid="B85" ref-type="bibr">85</xref>). Moderately, impaired neutrophil recruitment was also correlated with reduced IL-17 production and increased disease severity in mice in response to type I IFNs during <italic>F. tularensis</italic> and <italic>L. monocytogenes</italic> infections (<xref rid="B71" ref-type="bibr">71</xref>). However, it is debated whether or not neutrophils are protective during infections by <italic>L. monocytogenes</italic> and other intracellular bacteria (<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B106" ref-type="bibr">106</xref>). Moreover, the neutropenia seen in patients treated with type I IFNs fails to correlate with their susceptibility to bacterial infections (<xref rid="B86" ref-type="bibr">86</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Thus, type I IFNs can alter production of cytokines and chemokines involved in neutrophil or inflammatory macrophage recruitment.</p></sec><sec id="S5-3"><title>Suppression of myeloid cell responsiveness to IFN&#x003b3;</title><p>IFN&#x003b3; is critical for the pro-inflammatory anti-microbial (M1) type activation of macrophages and transgenic mice lacking responsiveness to IFN&#x003b3; selectively in myeloid cells are highly susceptible to <italic>L. monocytogenes</italic> and other intracellular pathogens (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B107" ref-type="bibr">107</xref>). The macrophages activated by IFN&#x003b3; have increased expression of molecules involved in both MHC class I and MHC class II antigen presentation, as well as enzymes producing reactive oxygen and nitrogen species with potential anti-microbial functions and pro-inflammatory cytokines and chemokines, including IL-12 (<xref rid="B19" ref-type="bibr">19</xref>). Expression of some, but not all, of these genes can also be induced when macrophages are stimulated with type I IFNs. In contrast, only IFN&#x003b3; stimulates macrophages to express or upregulate MHC class II molecules (<xref rid="B108" ref-type="bibr">108</xref>). Indeed, stimulation of macrophages with type I IFNs suppresses their induction of MHC II expression in response to IFN&#x003b3;. As mentioned above, type I IFNs also suppress production of IL-12 and CXCL1 and 2 (<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B96" ref-type="bibr">96</xref>). These data suggest that type I IFNs are able to prevent or dampen classical M1-type anti-microbial macrophage activation in response to IFN&#x003b3;. Consistent with this interpretation, a recent report revealed an inverse correlation between IFN&#x003b2; and IFN&#x003b3; gene expression patterns in lesions of human leprosy patients (<xref rid="B90" ref-type="bibr">90</xref>). The IFN&#x003b2;-driven response also correlated with IL-10 production, and IFN&#x003b2; production contributed to IL-10 secretion, leading the authors to conclude that the impaired IFN&#x003b3; responses in <italic>M. leprae</italic> infected macrophages is due to IL-10 production (<xref rid="B90" ref-type="bibr">90</xref>). Indeed, IFN&#x003b2; and IL-10 treatments both impaired the ability of IFN&#x003b3; to induce expression of the vitamin D receptor, the vitamin D-1a-hydroxylase, and the anti-microbial peptides cathelicidin and DEFB4 in macrophages (<xref rid="B90" ref-type="bibr">90</xref>).</p><p>Type I IFNs were also associated with the induction of IL-10 secretion and Programed death-ligand 1 (PD-L1) expression by myeloid cells during chronic LCMV infection (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). Experiments using antibody blockade of IFNAR showed reduced expression of these immune suppressive factors and increased clearance of persistent viral infections (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). Interestingly, the blockade of IFNAR also suppressed production of IL-1&#x003b2; and IL-18, arguing against the notion that improved viral clearance was due to increased inflammasome activation. Rather, the improved viral clearance was associated with increased serum IFN&#x003b3; and blockade of IFNAR failed to improve viral clearance in mice treated with antibody to block IFN&#x003b3; (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). The therapeutic effects of blocking type I IFN signaling also correlated with an improved ratio of stimulatory versus immune regulatory antigen-presenting cells (APCs) and enhanced antiviral T cell responses. Although the authors of one study further suggested that the suppression of inflammatory and immune responses in these studies reflected chronic type I IFN signaling (<xref rid="B109" ref-type="bibr">109</xref>), a second study observed that type I IFNs increased IL-10 secretion and PD-L1 expression by DCs as early as 1&#x02009;day post infection (<xref rid="B110" ref-type="bibr">110</xref>).</p><p>Leading up to these recent studies, prior efforts had also demonstrated suppressive effects of type I IFNs on myeloid cell activation during systemic <italic>L. monocytogenes</italic> infection of mice (<xref rid="B70" ref-type="bibr">70</xref>). In this model, the suppressive effects of type I IFNs correlate with reductions in myeloid cell surface IFNGR1. Similarly, surface IFNGR1 staining is significantly reduced on myeloid cells from <italic>M. tuberculosis</italic> infected patients compared to healthy control and effective treatment of these patients correlates with restored myeloid surface expression of IFNGR1 (<xref rid="B111" ref-type="bibr">111</xref>). IFNAR expression is necessary and recombinant type I IFNs are sufficient to trigger IFNGR1 down regulation in mouse and human myeloid, but not T cells (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B112" ref-type="bibr">112</xref>), suggesting this mechanism might contribute to a selective inhibition of myeloid cell responsiveness to IFN&#x003b3;. Indeed, the reduced expression of IFNGR1 correlates with decreased responsiveness to IFN&#x003b3; as indicated by reduced STAT1 phosphorylation and impaired induction of MHC class II expression in the context of <italic>L. monocytogenes</italic>, <italic>M. tuberculosis</italic>, and <italic>F. novicida</italic> infections (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B113" ref-type="bibr">113</xref>).</p><p>Additional mechanistic studies have revealed that type I IFNs suppress myeloid cell surface IFNGR1 within hours of stimulating the IFNAR and that this effect is due to transcriptional silencing of the otherwise constitutively expressed <italic>ifngr1</italic> gene (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B111" ref-type="bibr">111</xref>, <xref rid="B112" ref-type="bibr">112</xref>). The rapid reductions in <italic>ifngr1</italic> transcript abundance following IFN&#x003b2; stimulation are preceded by loss of activated RNA polymerase II at the <italic>ifngr1</italic> transcriptional start site and the accumulation of epigenetic marks on nearby histones that are indicative of condensed chromatin (<xref rid="B112" ref-type="bibr">112</xref>). The reduction in <italic>ifngr1</italic> transcription is also associated with recruitment of the early growth response 3 (Egr3) transcription factor shortly after IFN&#x003b2; treatment (<xref rid="B112" ref-type="bibr">112</xref>). Egr3 is a member of the Egr family of zinc finger transcription factors originally defined for their role in regulation of cell growth and differentiation (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Egr3 can act as an activator or repressor in response to various stimuli, depending on post-translational modifications and association with various adapter proteins (<xref rid="B114" ref-type="bibr">114</xref>&#x02013;<xref rid="B117" ref-type="bibr">117</xref>). One such adaptor protein, the NGFI-A binding protein Nab1 is a known corepressor and is also recruited to the <italic>ifngr1</italic> promoter shortly after Egr3 (<xref rid="B112" ref-type="bibr">112</xref>). Knockdown of Nab1, but not Nab2, prevented IFNGR1 down regulation in macrophages treated with IFN&#x003b2;, suggesting that recruitment of a repressive Egr3/Nab1 complex is responsible for rapid silencing of <italic>ifngr1</italic> transcription (<xref rid="B112" ref-type="bibr">112</xref>). Given that the half-life of IFNGR1 protein is estimated at 3&#x02013;4&#x02009;h (<xref rid="B118" ref-type="bibr">118</xref>), such transcriptional silencing is sufficient to rapidly reduce myeloid cell responsiveness to IFN&#x003b3;. Nonetheless, type I IFN stimulation does not appear to cause a complete loss of myeloid cell surface IFNGR1, possibly due to the induction of SOCS proteins and other endogenous negative feedback circuits that attenuate cellular responses to IFNAR signaling. These results suggest that down regulation of IFNGR1 expression might be an early step in the cascade of events leading to the suppression of myeloid cell responses that result in increased bacterial burdens and disease severity during acute and chronic bacterial infections, and the establishment or maintenance of chronic viral infections.</p></sec><sec id="S5-4"><title>Common features of proposed mechanisms</title><p>Given the numerous effects of type I IFNs on various cells of the immune system and on non-immune cells, it is plausible that their pro-pathogen effects vary for different pathogens. This seems particularly likely for pathogens infect different tissue or cell types, where the responses to type I IFNs may differ. For instance, a recent study demonstrated that IFNAR expression on non-hematopoietic cells was required to increase host susceptibility to the intracellular bacterial pathogen <italic>Ixodes ovatus Ehrlichia</italic> (<xref rid="B119" ref-type="bibr">119</xref>). The effects of these cytokines may also differ depending on the route of infection and the presence or nature of competing commensal microbes. For example, Kerbauer et al. suggested that type I IFNs might not be as detrimental to the host following gastric infection of mice with <italic>L. monocytogenes</italic> (<xref rid="B120" ref-type="bibr">120</xref>). Regardless, results from the studies highlighted above clearly implicate myeloid cells/APCs as key targets of type I IFNs in settings where these cytokines are deleterious to the host. Precisely, how these cytokines act to dampen myeloid cell immunity and what selective advantage this confers on the host remains to be discerned.</p></sec></sec><sec id="S6"><title>Apposing Effects of Type I IFNs in Autoimmune Diseases</title><p>The role of type I IFN signaling during autoimmune disease remains controversial, possibly indicating that these cytokines have opposing effects in different disease settings. For example, chronic type I IFN production is a hallmark of systemic lupus erythematosus (SLE) and several groups have reported a subset of ISGs upregulated in SLE patients compared to healthy controls (<xref rid="B121" ref-type="bibr">121</xref>&#x02013;<xref rid="B124" ref-type="bibr">124</xref>). ISG signatures were also associated with disease severity and progression in SLE patients (<xref rid="B121" ref-type="bibr">121</xref>&#x02013;<xref rid="B123" ref-type="bibr">123</xref>). It has thus been suggested that type I IFNs promote SLE pathology through the activation of effector cells. Type I IFNs can paradoxically promote not just death of lymphocytes, but also T cell survival, proliferation, cytotoxicity, and B cell differentiation and antibody production. Any of these effects might conceivably contribute to increased tissue damage and disease progression in SLE patients.</p><p>In contrast to the exacerbation of SLE by type I IFNs, these same cytokines confer therapeutic benefits in certain other autoimmune diseases. The most obvious example of this is the neuroinflammatory disease MS. IFN&#x003b2; is a common therapy and has been shown to reduce the frequency of clinical exacerbations in patients with relapse-remitting MS (<xref rid="B125" ref-type="bibr">125</xref>). The mechanisms for these beneficial effects remain uncertain. However, type I IFNs also suppress disease in the murine experimental autoimmune encephalomyelitis (EAE) model of MS. As for MS, IFN&#x003b2; is therapeutic in the EAE model and deletion of the <italic>ifnb</italic> gene or IFNAR1 robustly increased EAE pathogenesis in mice (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>). Furthermore, using conditional knockouts, it was shown that IFNAR1 expression on myeloid cells was specifically required for the therapeutic effects of IFN&#x003b2; during EAE (<xref rid="B127" ref-type="bibr">127</xref>). Deficiencies in IFNAR1 expression on myeloid cells also severely exacerbated disease and correlated with increased secretion of TNF&#x003b1; and CCL2 as well as increased expression of MHC II (<xref rid="B127" ref-type="bibr">127</xref>). These immunosuppressive effects of IFN&#x003b2; treatment in humans may likewise target myeloid cells.</p><p>Other autoimmune diseases where type I IFNs appear to play a protective role include collagen type II induced arthritis in non-human primates (<xref rid="B128" ref-type="bibr">128</xref>). Treatment with double-stranded RNA species or recombinant IFN&#x003b1; also lowered the frequency and severity of arthritic symptoms in the murine model of antigen-induced arthritis (<xref rid="B129" ref-type="bibr">129</xref>). The pharmacokinetics of IFN&#x003b2; therapies have shown to be a barrier is translating many of these treatments from animal models to clinical use in humans. However, Mullen et al. engineered a latent form of IFN&#x003b2; that can only become activated when cleaved by aggrecanase (<xref rid="B130" ref-type="bibr">130</xref>). Aggrecanases are highly expressed within the joints and synovial fluid of rheumatoid arthritis and osteoarthritis patients and are responsible for the cleavage of aggrecan, an important component of joint tissue (<xref rid="B130" ref-type="bibr">130</xref>). This delivery method allows for temporal and tissue specific release of IFN&#x003b2; that resulted in a significantly increased half-life of IFN&#x003b2; as well as reduced pathology and joint swelling from collagen induced arthritis (<xref rid="B130" ref-type="bibr">130</xref>).</p><p>Humans with autoimmunity often carry a single nucleotide mutation in protein tyrosine phosphatase non-receptor type 22 (PTPN22) (<xref rid="B131" ref-type="bibr">131</xref>). PTPN22 is an intracellular protein tyrosine phosphatase that is exclusively found in immune cells (<xref rid="B131" ref-type="bibr">131</xref>), and was recently associated with TLR signaling for type I IFN synthesis in myeloid cells (<xref rid="B132" ref-type="bibr">132</xref>). Functional PTPN22 was also shown to suppress inflammatory arthritis and promote gut homeostasis (<xref rid="B132" ref-type="bibr">132</xref>). Mice deficient in PTPN22 demonstrate increased susceptibility in the dextran sodium sulfate (DSS) mouse model of acute colitis (<xref rid="B132" ref-type="bibr">132</xref>). TLR stimulation by microbiota also induced immunosuppressive effects that correlated with type I IFN production and decreased progression of experimental colitis in mice (<xref rid="B133" ref-type="bibr">133</xref>). Treatment with recombinant IFN&#x003b2; phenocopied the decreased colitis achieved through TLR stimulation (<xref rid="B133" ref-type="bibr">133</xref>). Moreover, in a randomized placebo controlled study of active ulcerative colitis, a significant clinical response, and in some cases, disease remission, was seen in patients that received IFN&#x003b2; therapy compared to the patients that received placebo (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). It was noted that the therapeutic effects of IFN&#x003b2; treatment in this disease correlated with reduced production of IL-13, an effector cytokine driving intestinal inflammation (<xref rid="B134" ref-type="bibr">134</xref>). Mice deficient in type I IFN signaling have been shown to have exacerbated DSS-induced acute colitis (<xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B137" ref-type="bibr">137</xref>). Furthermore, mice with IFNAR1 deletion specifically in myeloid cells demonstrated significantly increased weight loss and colitis disease activity score when treated with DSS (<xref rid="B136" ref-type="bibr">136</xref>). These data suggest that type I IFN signaling specifically in myeloid cell is protective during DSS-induced acute colitis. Interestingly, the authors further showed that IFNAR1<sup>&#x02212;/&#x02212;</sup> mice recovered from DSS treatment more quickly than wild-type mice, suggesting a deleterious role of type I IFNs during the recovery phase of colitis (<xref rid="B136" ref-type="bibr">136</xref>).</p></sec><sec id="S7"><title>Conclusion</title><p>Interferons are important mediators and regulators of the immune response to viruses, bacteria, and other pathogens. They can suppress inflammatory responses and exacerbate the pathogenesis in certain autoimmune diseases and several intracellular bacterial infections. Indeed, pathogens such as <italic>L. monocytogenes</italic> may actively promote type I IFN production through secretion of nucleic acids or cyclic-di-nucleotides that are recognized by cytosolic pattern recognition receptors to stimulate a type I IFN response. However, type I IFNs appear to be protective in certain other bacterial infections and in many viral infections, and may exacerbate the autoimmune disease SLE. Thus, blindly blocking their production as a therapy for bacterial infections would likely have severe untoward effects in these other disease settings. It thus remains an important challenge to dissect the mechanisms for the divergent pro- and anti-inflammatory effects of type I IFNs, as well as their paradoxical protective and deleterious effects during infectious and other diseases. As we review here, a number of observations have been correlated with the pro-bacterial effects of type I IFNs. However, while these observations have led to the proposal of several differing mechanisms to explain these detrimental effects of type I IFNs during intracellular bacterial infections, a common theme is the suppression of myeloid cell inflammatory responses. Whether such suppression results from the induction of effector cell death and IL-10 production, suppression of T cell cytokine or chemokine production, suppression of inflammasomes, or down modulation of IFNGR expression remains to be seen. However, even in the absence of experimental proof that points to a specific mechanism, it is attractive to speculate that the deleterious effects of type I IFN signaling during bacterial infections are tolerated because their ability to suppress myeloid cell responses also has a beneficial effect in protecting the host from MS and other autoimmune diseases.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>Laurel L. Lenz serves on editorial boards for Frontiers in Immunology and Frontiers in Microbiology. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>Our work on interferon responses and <italic>L. monocytogenes</italic> is supported by NIH grants AI065638, AI102264, and AI103782. Emily M. Eshleman received support from NIH training grant AI052066.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platanias</surname><given-names>LC</given-names></name></person-group><article-title>Mechanisms of type-I- and type-II-interferon-mediated signalling</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>:<fpage>375</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1038/nri1604</pub-id><?supplied-pmid 15864272?><pub-id pub-id-type="pmid">15864272</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borden</surname><given-names>EC</given-names></name><name><surname>Sen</surname><given-names>GC</given-names></name><name><surname>Uze</surname><given-names>G</given-names></name><name><surname>Silverman</surname><given-names>RH</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Foster</surname><given-names>GR</given-names></name><etal/></person-group>
<article-title>Interferons at age 50: past, current and future impact on biomedicine</article-title>. <source>Nat Rev Drug Discov</source> (<year>2007</year>) <volume>6</volume>:<fpage>975</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nrd2422</pub-id><?supplied-pmid 18049472?><pub-id pub-id-type="pmid">18049472</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Chevillotte</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group>
<article-title>Interferon-stimulated genes: a complex web of host defenses</article-title>. <source>Annu Rev Immunol</source> (<year>2014</year>) <volume>32</volume>:<fpage>513</fpage>&#x02013;<lpage>45</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><?supplied-pmid 24555472?><pub-id pub-id-type="pmid">24555472</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestka</surname><given-names>S</given-names></name></person-group>
<article-title>The interferons: 50 years after their discovery, there is much more to learn</article-title>. <source>J Biol Chem</source> (<year>2007</year>) <volume>282</volume>:<fpage>20047</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1074/jbc.R700004200</pub-id><?supplied-pmid 17502369?><pub-id pub-id-type="pmid">17502369</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>S</given-names></name><name><surname>Delgado</surname><given-names>C</given-names></name><name><surname>Lenz</surname><given-names>LL</given-names></name></person-group>
<article-title>Differential effects of type I and II interferons on myeloid cells and resistance to intracellular bacterial infections</article-title>. <source>Immunol Res</source> (<year>2012</year>) <volume>55</volume>:<fpage>187</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="doi">10.1007/s12026-012-8362-y</pub-id><?supplied-pmid 22983898?><pub-id pub-id-type="pmid">22983898</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracarda</surname><given-names>S</given-names></name><name><surname>Eggermont</surname><given-names>AMM</given-names></name><name><surname>Samuelsson</surname><given-names>J</given-names></name></person-group>
<article-title>Redefining the role of interferon in the treatment of malignant diseases</article-title>. <source>Eur J Cancer</source> (<year>2010</year>) <volume>46</volume>:<fpage>284</fpage>&#x02013;<lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.10.013</pub-id><?supplied-pmid 19906524?><pub-id pub-id-type="pmid">19906524</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Boxel-Dezaire</surname><given-names>AHH</given-names></name><name><surname>Rani</surname><given-names>MRS</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group>
<article-title>Complex modulation of cell type-specific signaling in response to type I interferons</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>25</volume>:<fpage>361</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.014</pub-id><?supplied-pmid 16979568?><pub-id pub-id-type="pmid">16979568</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name><name><surname>Levin</surname><given-names>D</given-names></name><name><surname>Krutzik</surname><given-names>PO</given-names></name><name><surname>Podoplelova</surname><given-names>Y</given-names></name><name><surname>Trejo</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Structural linkage between ligand discrimination and receptor activation by type I interferons</article-title>. <source>Cell</source> (<year>2011</year>) <volume>146</volume>:<fpage>621</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.048</pub-id><?supplied-pmid 21854986?><pub-id pub-id-type="pmid">21854986</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>RE</given-names></name><name><surname>Crossley</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Forman</surname><given-names>J</given-names></name></person-group>
<article-title>Memory CD8+ T cells provide innate immune protection against <italic>Listeria monocytogenes</italic> in the absence of cognate antigen</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>198</volume>:<fpage>1583</fpage>&#x02013;<lpage>93</lpage><pub-id pub-id-type="doi">10.1084/jem.20031051</pub-id><?supplied-pmid 14623912?><pub-id pub-id-type="pmid">14623912</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humann</surname><given-names>J</given-names></name><name><surname>Lenz</surname><given-names>LL</given-names></name></person-group>
<article-title>Activation of naive NK cells in response to <italic>Listeria monocytogenes</italic> requires IL-18 and contact with infected dendritic cells</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<fpage>5172</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903759</pub-id><pub-id pub-id-type="pmid">20351186</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soudja</surname><given-names>SM</given-names></name><name><surname>Ruiz</surname><given-names>AL</given-names></name><name><surname>Marie</surname><given-names>JC</given-names></name><name><surname>Lauvau</surname><given-names>G</given-names></name></person-group>
<article-title>Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>:<fpage>549</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.05.029</pub-id><?supplied-pmid 22940097?><pub-id pub-id-type="pmid">22940097</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dighe</surname><given-names>AS</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Greaves</surname><given-names>DR</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Tissue-specific targeting of cytokine unresponsiveness in transgenic mice</article-title>. <source>Immunity</source> (<year>1995</year>) <volume>3</volume>:<fpage>657</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="doi">10.1016/1074-7613(95)90136-1</pub-id><?supplied-pmid 7584155?><pub-id pub-id-type="pmid">7584155</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Carrero</surname><given-names>JA</given-names></name><name><surname>Uppaluri</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Archambault</surname><given-names>JM</given-names></name><name><surname>Lai</surname><given-names>KS</given-names></name><etal/></person-group>
<article-title>Identifying the initiating events of anti-<italic>Listeria</italic> responses using mice with conditional loss of IFN-&#x003b3; receptor subunit 1 (IFNGR1)</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>:<fpage>4223</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300910</pub-id><?supplied-pmid 24048899?><pub-id pub-id-type="pmid">24048899</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMicking</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Nathan</surname><given-names>C</given-names></name></person-group>
<article-title>Nitric oxide and macrophage function</article-title>. <source>Annu Rev Immunol</source> (<year>1997</year>) <volume>15</volume>:<fpage>323</fpage>&#x02013;<lpage>50</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.15.1.323</pub-id><?supplied-pmid 9143691?><pub-id pub-id-type="pmid">9143691</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumatori</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name></person-group>
<article-title>Cooperation of STAT-1 and IRF-1 in interferon-gamma-induced transcription of the gp91(phox) gene</article-title>. <source>J Biol Chem</source> (<year>2002</year>) <volume>277</volume>:<fpage>9103</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109803200</pub-id><?supplied-pmid 11781315?><pub-id pub-id-type="pmid">11781315</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunn</surname><given-names>JP</given-names></name><name><surname>Feng</surname><given-names>CG</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Howard</surname><given-names>JC</given-names></name></person-group>
<article-title>The immunity-related GTPases in mammals: a fast-evolving cell-autonomous resistance system against intracellular pathogens</article-title>. <source>Mamm Genome</source> (<year>2011</year>) <volume>22</volume>:<fpage>43</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s00335-010-9293-3</pub-id><?supplied-pmid 21052678?><pub-id pub-id-type="pmid">21052678</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B-H</given-names></name><name><surname>Shenoy</surname><given-names>AR</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Bradfield</surname><given-names>CJ</given-names></name><name><surname>MacMicking</surname><given-names>JD</given-names></name></person-group>
<article-title>IFN-inducible GTPases in host cell defense</article-title>. <source>Cell Host Microbe</source> (<year>2012</year>) <volume>12</volume>:<fpage>432</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.09.007</pub-id><?supplied-pmid 23084913?><pub-id pub-id-type="pmid">23084913</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>GA</given-names></name><name><surname>Feng</surname><given-names>CG</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group>
<article-title>Control of IFN-gamma-mediated host resistance to intracellular pathogens by immunity-related GTPases (p47 GTPases)</article-title>. <source>Microbes Infect</source> (<year>2007</year>) <volume>9</volume>:<fpage>1644</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2007.09.004</pub-id><?supplied-pmid 18023232?><pub-id pub-id-type="pmid">18023232</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><name><surname>Ravasi</surname><given-names>T</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name></person-group>
<article-title>Interferon-gamma: an overview of signals, mechanisms and functions</article-title>. <source>J Leukoc Biol</source> (<year>2004</year>) <volume>75</volume>:<fpage>164</fpage>&#x02013;<lpage>89</lpage><pub-id pub-id-type="doi">10.1189/jlb.0603252.Journal</pub-id><?supplied-pmid 14525967?><pub-id pub-id-type="pmid">14525967</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Weksberg</surname><given-names>DC</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group>
<article-title>Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection</article-title>. <source>Nature</source> (<year>2010</year>) <volume>465</volume>:<fpage>793</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature09135</pub-id><?supplied-pmid 20535209?><pub-id pub-id-type="pmid">20535209</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNamara</surname><given-names>KC</given-names></name><name><surname>Oduro</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>O</given-names></name><name><surname>Jones</surname><given-names>DD</given-names></name><name><surname>McLaughlin</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-&#x003b3; signaling</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<fpage>1032</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001893</pub-id><?supplied-pmid 21149601?><pub-id pub-id-type="pmid">21149601</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayamajhi</surname><given-names>M</given-names></name><name><surname>Humann</surname><given-names>J</given-names></name><name><surname>Kearney</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>KK</given-names></name><name><surname>Lenz</surname><given-names>LL</given-names></name></person-group>
<article-title>Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections</article-title>. <source>Virulence</source> (<year>2010</year>) <volume>1</volume>:<fpage>418</fpage>&#x02013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1084/jem.20091746.ype</pub-id><?supplied-pmid 21178482?><pub-id pub-id-type="pmid">21178482</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Stockinger</surname><given-names>S</given-names></name></person-group>
<article-title>The yin and yang of type I interferon activity in bacterial infection</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>:<fpage>675</fpage>&#x02013;<lpage>87</lpage><pub-id pub-id-type="doi">10.1038/nri1684</pub-id><?supplied-pmid 16110316?><pub-id pub-id-type="pmid">16110316</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Kanneganti</surname><given-names>T-D</given-names></name></person-group>
<article-title>Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2013</year>) <volume>3</volume>:<fpage>77</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2013.00077</pub-id><?supplied-pmid 24273750?><pub-id pub-id-type="pmid">24273750</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostowy</surname><given-names>S</given-names></name><name><surname>Cossart</surname><given-names>P</given-names></name></person-group>
<article-title>Cytoskeleton rearrangements during <italic>Listeria</italic> infection: clathrin and septins as new players in the game</article-title>. <source>Cell Motil Cytoskeleton</source> (<year>2009</year>) <volume>66</volume>:<fpage>816</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1002/cm.20353</pub-id><?supplied-pmid 19296488?><pub-id pub-id-type="pmid">19296488</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ireton</surname><given-names>K</given-names></name></person-group>
<article-title>Entry of the bacterial pathogen <italic>Listeria monocytogenes</italic> into mammalian cells</article-title>. <source>Cell Microbiol</source> (<year>2007</year>) <volume>9</volume>:<fpage>1365</fpage>&#x02013;<lpage>75</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.00933.x</pub-id><?supplied-pmid 17419717?><pub-id pub-id-type="pmid">17419717</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portnoy</surname><given-names>D</given-names></name><name><surname>Jacks</surname><given-names>P</given-names></name><name><surname>Hinrichs</surname><given-names>D</given-names></name></person-group>
<article-title>Role of hemolysin for the intracellular growth of <italic>Listeria monocytogenes</italic></article-title>. <source>J Exp Med</source> (<year>1988</year>) <volume>167</volume>:<fpage>1459</fpage>&#x02013;<lpage>71</lpage><pub-id pub-id-type="doi">10.1084/jem.167.4.1459</pub-id><?supplied-pmid 2833557?><pub-id pub-id-type="pmid">2833557</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCaffrey</surname><given-names>RL</given-names></name><name><surname>Fawcett</surname><given-names>P</given-names></name><name><surname>O&#x02019;Riordan</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K-D</given-names></name><name><surname>Havell</surname><given-names>EA</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><etal/></person-group>
<article-title>A specific gene expression program triggered by Gram-positive bacteria in the cytosol</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2004</year>) <volume>101</volume>:<fpage>11386</fpage>&#x02013;<lpage>91</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403215101</pub-id><?supplied-pmid 15269347?><pub-id pub-id-type="pmid">15269347</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leber</surname><given-names>JH</given-names></name><name><surname>Crimmins</surname><given-names>GT</given-names></name><name><surname>Raghavan</surname><given-names>S</given-names></name><name><surname>Meyer-Morse</surname><given-names>NP</given-names></name><name><surname>Cox</surname><given-names>JS</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name></person-group>
<article-title>Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen</article-title>. <source>PLoS Pathog</source> (<year>2008</year>) <volume>4</volume>:<fpage>e6</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0040006</pub-id><?supplied-pmid 18193943?><pub-id pub-id-type="pmid">18193943</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubry</surname><given-names>C</given-names></name><name><surname>Corr</surname><given-names>SC</given-names></name><name><surname>Wienerroither</surname><given-names>S</given-names></name><name><surname>Goulard</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Jamieson</surname><given-names>AM</given-names></name><etal/></person-group>
<article-title>Both TLR2 and TRIF contribute to interferon-&#x003b2; production during <italic>Listeria</italic> infection</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e33299</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0033299</pub-id><?supplied-pmid 22432012?><pub-id pub-id-type="pmid">22432012</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J-H</given-names></name><name><surname>Kim</surname><given-names>Y-G</given-names></name><name><surname>McDonald</surname><given-names>C</given-names></name><name><surname>Kanneganti</surname><given-names>T-D</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Body-Malapel</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>:<fpage>2380</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2380</pub-id><?supplied-pmid 17277144?><pub-id pub-id-type="pmid">17277144</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Inohara</surname><given-names>N</given-names></name><name><surname>Hernandez</surname><given-names>LD</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>JE</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>G</given-names></name><name><surname>Janeway</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems</article-title>. <source>Nature</source> (<year>2002</year>) <volume>416</volume>:<fpage>194</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/416194a</pub-id><?supplied-pmid 11894098?><pub-id pub-id-type="pmid">11894098</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>AI</given-names></name><name><surname>Dempsey</surname><given-names>PW</given-names></name><name><surname>Bruhn</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>JF</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group>
<article-title>Involvement of receptor-interacting protein 2 in innate and adaptive immune responses</article-title>. <source>Nature</source> (<year>2002</year>) <volume>416</volume>:<fpage>190</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="doi">10.1038/416190a</pub-id><?supplied-pmid 11894097?><pub-id pub-id-type="pmid">11894097</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connell</surname><given-names>R</given-names></name><name><surname>Vaidya</surname><given-names>S</given-names></name><name><surname>Perry</surname><given-names>AK</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Dempsey</surname><given-names>PW</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group>
<article-title>Immune activation of type I IFNs by <italic>Listeria monocytogenes</italic> occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TANK-binding kinase</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>174</volume>:<fpage>1602</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.3.1602</pub-id><?supplied-pmid 15661922?><pub-id pub-id-type="pmid">15661922</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockinger</surname><given-names>S</given-names></name><name><surname>Reutterer</surname><given-names>B</given-names></name><name><surname>Schaljo</surname><given-names>B</given-names></name><name><surname>Schellack</surname><given-names>C</given-names></name><name><surname>Brunner</surname><given-names>S</given-names></name><name><surname>Materna</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>:<fpage>7416</fpage>&#x02013;<lpage>25</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.12.7416</pub-id><?supplied-pmid 15585867?><pub-id pub-id-type="pmid">15585867</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetson</surname><given-names>DB</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>
<article-title>Recognition of cytosolic DNA activates an IRF3-dependent innate immune response</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>24</volume>:<fpage>93</fpage>&#x02013;<lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.12.003</pub-id><?supplied-pmid 16413926?><pub-id pub-id-type="pmid">16413926</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdullah</surname><given-names>Z</given-names></name><name><surname>Schlee</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>S</given-names></name><name><surname>Mraheil</surname><given-names>MA</given-names></name><name><surname>Barchet</surname><given-names>W</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>RIG-I detects infection with live <italic>Listeria</italic> by sensing secreted bacterial nucleic acids</article-title>. <source>EMBO J</source> (<year>2012</year>) <volume>31</volume>:<fpage>4153</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.274</pub-id><?supplied-pmid 23064150?><pub-id pub-id-type="pmid">23064150</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>Y-M</given-names></name><name><surname>Gale</surname><given-names>M</given-names></name></person-group>
<article-title>Immune signaling by RIG-I-like receptors</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>680</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.003</pub-id><pub-id pub-id-type="pmid">21616437</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vabret</surname><given-names>N</given-names></name><name><surname>Blander</surname><given-names>JM</given-names></name></person-group>
<article-title>Sensing microbial RNA in the cytosol</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>468</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00468</pub-id><?supplied-pmid 24400006?><pub-id pub-id-type="pmid">24400006</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>
<article-title>Innate immune sensing and signaling of cytosolic nucleic acids</article-title>. <source>Annu Rev Immunol</source> (<year>2014</year>) <volume>32</volume>:<fpage>461</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120156</pub-id><?supplied-pmid 24655297?><pub-id pub-id-type="pmid">24655297</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>RB</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Ea</surname><given-names>C-K</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group>
<article-title>Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3</article-title>. <source>Cell</source> (<year>2005</year>) <volume>122</volume>:<fpage>669</fpage>&#x02013;<lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.012</pub-id><?supplied-pmid 16125763?><pub-id pub-id-type="pmid">16125763</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L-G</given-names></name><name><surname>Wang</surname><given-names>Y-Y</given-names></name><name><surname>Han</surname><given-names>K-J</given-names></name><name><surname>Li</surname><given-names>L-Y</given-names></name><name><surname>Zhai</surname><given-names>Z</given-names></name><name><surname>Shu</surname><given-names>H-B</given-names></name></person-group>
<article-title>VISA is an adapter protein required for virus-triggered IFN-beta signaling</article-title>. <source>Mol Cell</source> (<year>2005</year>) <volume>19</volume>:<fpage>727</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.08.014</pub-id><?supplied-pmid 16153868?><pub-id pub-id-type="pmid">16153868</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Curran</surname><given-names>J</given-names></name><name><surname>Hofmann</surname><given-names>K</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name><name><surname>Bartenschlager</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus</article-title>. <source>Nature</source> (<year>2005</year>) <volume>437</volume>:<fpage>1167</fpage>&#x02013;<lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nature04193</pub-id><?supplied-pmid 16177806?><pub-id pub-id-type="pmid">16177806</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H-H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Seth</surname><given-names>RB</given-names></name><name><surname>Forman</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The specific and essential role of MAVS in antiviral innate immune responses</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>24</volume>:<fpage>633</fpage>&#x02013;<lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.04.004</pub-id><?supplied-pmid 16713980?><pub-id pub-id-type="pmid">16713980</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soulat</surname><given-names>D</given-names></name><name><surname>Bauch</surname><given-names>A</given-names></name><name><surname>Stockinger</surname><given-names>S</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name></person-group>
<article-title>Cytoplasmic <italic>Listeria monocytogenes</italic> stimulates IFN-beta synthesis without requiring the adapter protein MAVS</article-title>. <source>FEBS Lett</source> (<year>2006</year>) <volume>580</volume>:<fpage>2341</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.03.057</pub-id><?supplied-pmid 16616525?><pub-id pub-id-type="pmid">16616525</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagmann</surname><given-names>CA</given-names></name><name><surname>Herzner</surname><given-names>AM</given-names></name><name><surname>Abdullah</surname><given-names>Z</given-names></name><name><surname>Zillinger</surname><given-names>T</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name><name><surname>Schuberth</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>RIG-I detects triphosphorylated RNA of <italic>Listeria monocytogenes</italic> during infection in non-immune cells</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e62872</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0062872</pub-id><?supplied-pmid 23653683?><pub-id pub-id-type="pmid">23653683</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>McWhirter</surname><given-names>SM</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group>
<article-title>Identification of host cytosolic sensors and bacterial factors regulating the type I interferon response to <italic>Legionella pneumophila</italic></article-title>. <source>PLoS Pathog</source> (<year>2009</year>) <volume>5</volume>:<fpage>e1000665</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000665</pub-id><?supplied-pmid 19936053?><pub-id pub-id-type="pmid">19936053</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unterholzner</surname><given-names>L</given-names></name><name><surname>Keating</surname><given-names>SE</given-names></name><name><surname>Baran</surname><given-names>M</given-names></name><name><surname>Horan</surname><given-names>KA</given-names></name><name><surname>Jensen</surname><given-names>SB</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>IFI16 is an innate immune sensor for intracellular DNA</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>:<fpage>997</fpage>&#x02013;<lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/ni.1932</pub-id><?supplied-pmid 20890285?><pub-id pub-id-type="pmid">20890285</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>An</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Rui</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>:<fpage>487</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1038/ni.1876</pub-id><?supplied-pmid 20453844?><pub-id pub-id-type="pmid">20453844</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippmann</surname><given-names>J</given-names></name><name><surname>Rothenburg</surname><given-names>S</given-names></name><name><surname>Deigendesch</surname><given-names>N</given-names></name><name><surname>Eitel</surname><given-names>J</given-names></name><name><surname>Meixenberger</surname><given-names>K</given-names></name><name><surname>van Laak</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>IFNbeta responses induced by intracellular bacteria or cytosolic DNA in different human cells do not require ZBP1 (DLM-1/DAI)</article-title>. <source>Cell Microbiol</source> (<year>2008</year>) <volume>10</volume>:<fpage>2579</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2008.01232.x</pub-id><?supplied-pmid 18771559?><pub-id pub-id-type="pmid">18771559</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>K</given-names></name><name><surname>Prabakaran</surname><given-names>T</given-names></name><name><surname>Laustsen</surname><given-names>A</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>SE</given-names></name><name><surname>Rahb&#x000e6;k</surname><given-names>SH</given-names></name><name><surname>Jensen</surname><given-names>SB</given-names></name><etal/></person-group>
<article-title><italic>Listeria monocytogenes</italic> induces IFN&#x003b2; expression through an IFI16-, cGAS- and STING-dependent pathway</article-title>. <source>EMBO J</source> (<year>2014</year>) <volume>33</volume>:<fpage>1654</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="doi">10.15252/embj.201488029</pub-id><?supplied-pmid 24970844?><pub-id pub-id-type="pmid">24970844</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Bao</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y-J</given-names></name></person-group>
<article-title>The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells</article-title>. <source>Nat Immunol</source> (<year>2011</year>) <volume>12</volume>:<fpage>959</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="doi">10.1038/ni.2091</pub-id><?supplied-pmid 21892174?><pub-id pub-id-type="pmid">21892174</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Ogasawara</surname><given-names>K</given-names></name><name><surname>Takaoka</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name></person-group>
<article-title>IRF family of transcription factors as regulators of host defense</article-title>. <source>Annu Rev Immunol</source> (<year>2001</year>) <volume>19</volume>:<fpage>623</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.623</pub-id><?supplied-pmid 11244049?><pub-id pub-id-type="pmid">11244049</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connell</surname><given-names>RM</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Vaidya</surname><given-names>SA</given-names></name><name><surname>Bruhn</surname><given-names>KW</given-names></name><name><surname>Miranda</surname><given-names>GA</given-names></name><name><surname>Zarnegar</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Type I interferon production enhances susceptibility to <italic>Listeria monocytogenes</italic> infection</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>:<fpage>437</fpage>&#x02013;<lpage>45</lpage><pub-id pub-id-type="doi">10.1084/jem.20040712</pub-id><?supplied-pmid 15302901?><pub-id pub-id-type="pmid">15302901</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Barber</surname><given-names>GN</given-names></name></person-group>
<article-title>STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity</article-title>. <source>Nature</source> (<year>2009</year>) <volume>461</volume>:<fpage>788</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1038/nature08476</pub-id><?supplied-pmid 19776740?><pub-id pub-id-type="pmid">19776740</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>KK</given-names></name><name><surname>Filak</surname><given-names>H</given-names></name><name><surname>Mogan</surname><given-names>J</given-names></name><name><surname>Knowles</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<fpage>2595</fpage>&#x02013;<lpage>601</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100088</pub-id><?supplied-pmid 21813776?><pub-id pub-id-type="pmid">21813776</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>J-D</given-names></name><name><surname>Sotelo-Troha</surname><given-names>K</given-names></name><name><surname>von Moltke</surname><given-names>J</given-names></name><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Rae</surname><given-names>CS</given-names></name><name><surname>Brubaker</surname><given-names>SW</given-names></name><etal/></person-group>
<article-title>The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of STING in the in vivo interferon response to <italic>Listeria monocytogenes</italic> and cyclic dinucleotides</article-title>. <source>Infect Immun</source> (<year>2011</year>) <volume>79</volume>:<fpage>688</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1128/IAI.00999-10</pub-id><?supplied-pmid 21098106?><pub-id pub-id-type="pmid">21098106</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>:<fpage>826</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.1126/science.1229963</pub-id><?supplied-pmid 23258412?><pub-id pub-id-type="pmid">23258412</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING</article-title>. <source>Mol Cell</source> (<year>2013</year>) <volume>51</volume>:<fpage>226</fpage>&#x02013;<lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.05.022</pub-id><?supplied-pmid 23747010?><pub-id pub-id-type="pmid">23747010</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdette</surname><given-names>DL</given-names></name><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Sotelo-Troha</surname><given-names>K</given-names></name><name><surname>Iwig</surname><given-names>JS</given-names></name><name><surname>Eckert</surname><given-names>B</given-names></name><name><surname>Hyodo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>STING is a direct innate immune sensor of cyclic di-GMP</article-title>. <source>Nature</source> (<year>2011</year>) <volume>478</volume>:<fpage>515</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature10429</pub-id><?supplied-pmid 21947006?><pub-id pub-id-type="pmid">21947006</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>JJ</given-names></name><name><surname>Iavarone</surname><given-names>AT</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name></person-group>
<article-title>c-di-AMP secreted by intracellular <italic>Listeria monocytogenes</italic> activates a host type I interferon response</article-title>. <source>Science</source> (<year>2010</year>) <volume>328</volume>:<fpage>1703</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.1189801</pub-id><?supplied-pmid 20508090?><pub-id pub-id-type="pmid">20508090</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>CE</given-names></name><name><surname>Whiteley</surname><given-names>AT</given-names></name><name><surname>Burke</surname><given-names>TP</given-names></name><name><surname>Sauer</surname><given-names>J-D</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name><name><surname>Woodward</surname><given-names>JJ</given-names></name></person-group>
<article-title>Cyclic di-AMP is critical for <italic>Listeria monocytogenes</italic> growth, cell wall homeostasis, and establishment of infection</article-title>. <source>MBio</source> (<year>2013</year>) <volume>4</volume>:<fpage>e282</fpage>&#x02013;<lpage>213</lpage><pub-id pub-id-type="doi">10.1128/mBio.00282-13</pub-id><?supplied-pmid 23716572?><pub-id pub-id-type="pmid">23716572</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plumlee</surname><given-names>CR</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>Shuman</surname><given-names>HA</given-names></name><name><surname>Schindler</surname><given-names>C</given-names></name></person-group>
<article-title>Interferons direct an effective innate response to <italic>Legionella pneumophila</italic> infection</article-title>. <source>J Biol Chem</source> (<year>2009</year>) <volume>284</volume>:<fpage>30058</fpage>&#x02013;<lpage>66</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.018283</pub-id><?supplied-pmid 19720834?><pub-id pub-id-type="pmid">19720834</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>G</given-names></name><name><surname>Midiri</surname><given-names>A</given-names></name><name><surname>Biondo</surname><given-names>C</given-names></name><name><surname>Beninati</surname><given-names>C</given-names></name><name><surname>Zummo</surname><given-names>S</given-names></name><name><surname>Galbo</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>:<fpage>3126</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.5.3126</pub-id><?supplied-pmid 17312160?><pub-id pub-id-type="pmid">17312160</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>T</given-names></name><name><surname>Aga</surname><given-names>M</given-names></name><name><surname>Hino</surname><given-names>K</given-names></name><name><surname>Ushio</surname><given-names>C</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Iwaki</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Inhibition of chlamydia trachomatis growth by human interferon-alpha: mechanisms and synergistic effect with interferon-gamma and tumor necrosis factor-alpha</article-title>. <source>Biomed Res</source> (<year>2005</year>) <volume>26</volume>:<fpage>179</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.2220/biomedres.26.179</pub-id><?supplied-pmid 16152734?><pub-id pub-id-type="pmid">16152734</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>KY</given-names></name><name><surname>Mangan</surname><given-names>NE</given-names></name><name><surname>Cumming</surname><given-names>H</given-names></name><name><surname>Horvat</surname><given-names>JC</given-names></name><name><surname>Mayall</surname><given-names>JR</given-names></name><name><surname>Stifter</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>Interferon-&#x003f5; protects the female reproductive tract from viral and bacterial infection</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>:<fpage>1088</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1126/science.1233321</pub-id><?supplied-pmid 23449591?><pub-id pub-id-type="pmid">23449591</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>BT</given-names></name><name><surname>Schoedon</surname><given-names>G</given-names></name><name><surname>Odermatt</surname><given-names>B</given-names></name><name><surname>Holtschke</surname><given-names>T</given-names></name><name><surname>Schneemann</surname><given-names>M</given-names></name><name><surname>Bachmann</surname><given-names>MF</given-names></name><etal/></person-group>
<article-title>Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis</article-title>. <source>J Exp Med</source> (<year>1997</year>) <volume>185</volume>:<fpage>921</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1084/jem.185.5.921</pub-id><?supplied-pmid 9120398?><pub-id pub-id-type="pmid">9120398</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auerbuch</surname><given-names>V</given-names></name><name><surname>Brockstedt</surname><given-names>DG</given-names></name><name><surname>Meyer-Morse</surname><given-names>N</given-names></name><name><surname>O&#x02019;Riordan</surname><given-names>M</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name></person-group>
<article-title>Mice lacking the type I interferon receptor are resistant to <italic>Listeria monocytogenes</italic></article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>:<fpage>527</fpage>&#x02013;<lpage>33</lpage><pub-id pub-id-type="doi">10.1084/jem.20040976</pub-id><?supplied-pmid 15302899?><pub-id pub-id-type="pmid">15302899</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrero</surname><given-names>JA</given-names></name><name><surname>Calderon</surname><given-names>B</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group>
<article-title>Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to <italic>Listeria</italic> infection</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>:<fpage>535</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1084/jem.20040769</pub-id><?supplied-pmid 15302900?><pub-id pub-id-type="pmid">15302900</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayamajhi</surname><given-names>M</given-names></name><name><surname>Humann</surname><given-names>J</given-names></name><name><surname>Penheiter</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>K</given-names></name><name><surname>Lenz</surname><given-names>LL</given-names></name></person-group>
<article-title>Induction of IFN-alphabeta enables <italic>Listeria monocytogenes</italic> to suppress macrophage activation by IFN-gamma</article-title>. <source>J Exp Med</source> (<year>2010</year>) <volume>207</volume>:<fpage>327</fpage>&#x02013;<lpage>37</lpage><pub-id pub-id-type="doi">10.1084/jem.20091746</pub-id><?supplied-pmid 20123961?><pub-id pub-id-type="pmid">20123961</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Kirimanjeswara</surname><given-names>GS</given-names></name><name><surname>Ruby</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>JW</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Perret</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<fpage>3755</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902065</pub-id><?supplied-pmid 20176744?><pub-id pub-id-type="pmid">20176744</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manca</surname><given-names>C</given-names></name><name><surname>Tsenova</surname><given-names>L</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Barczak</surname><given-names>AK</given-names></name><name><surname>Tovey</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Hypervirulent <italic>M. tuberculosis</italic> W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway</article-title>. <source>J Interf Cytokine Res</source> (<year>2005</year>) <volume>701</volume>:<fpage>694</fpage>&#x02013;<lpage>701</lpage><pub-id pub-id-type="doi">10.1089/jir.2005.25.694</pub-id><?supplied-pmid 16318583?><pub-id pub-id-type="pmid">16318583</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvignes</surname><given-names>L</given-names></name><name><surname>Wolf</surname><given-names>AJ</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group>
<article-title>Dynamic roles of type I and type II IFNs in early infection with <italic>Mycobacterium tuberculosis</italic></article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<fpage>6205</fpage>&#x02013;<lpage>15</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200255</pub-id><?supplied-pmid 22566567?><pub-id pub-id-type="pmid">22566567</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Andrade</surname><given-names>BB</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Hieny</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>CG</given-names></name><name><surname>Caspar</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Innate and adaptive interferons suppress IL-1&#x003b1; and IL-1&#x003b2; production by distinct pulmonary myeloid subsets during <italic>Mycobacterium tuberculosis</italic> infection</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>35</volume>:<fpage>1023</fpage>&#x02013;<lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.12.002</pub-id><?supplied-pmid 22195750?><pub-id pub-id-type="pmid">22195750</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarajan</surname><given-names>UM</given-names></name><name><surname>Prantner</surname><given-names>D</given-names></name><name><surname>Sikes</surname><given-names>JD</given-names></name><name><surname>Andrews</surname><given-names>CW</given-names></name><name><surname>Goodwin</surname><given-names>AM</given-names></name><name><surname>Nagarajan</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Type I interferon signaling exacerbates <italic>Chlamydia muridarum</italic> genital infection in a murine model</article-title>. <source>Infect Immun</source> (<year>2008</year>) <volume>76</volume>:<fpage>4642</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1128/IAI.00629-08</pub-id><?supplied-pmid 18663004?><pub-id pub-id-type="pmid">18663004</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Joyee</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Type I IFNs enhance susceptibility to <italic>Chlamydia muridarum</italic> lung infection by enhancing apoptosis of local macrophages</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<fpage>2092</fpage>&#x02013;<lpage>102</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.3.2092</pub-id><?supplied-pmid 18641348?><pub-id pub-id-type="pmid">18641348</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richer</surname><given-names>E</given-names></name><name><surname>Prendergast</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>D-E</given-names></name><name><surname>Qureshi</surname><given-names>ST</given-names></name><name><surname>Vidal</surname><given-names>SM</given-names></name><name><surname>Malo</surname><given-names>D</given-names></name></person-group>
<article-title>N-ethyl-N-nitrosourea-induced mutation in ubiquitin-specific peptidase 18 causes hyperactivation of IFN-&#x003b1;&#x000df; signaling and suppresses STAT4-induced IFN-&#x003b3; production, resulting in increased susceptibility to <italic>Salmonella typhimurium</italic></article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>:<fpage>3593</fpage>&#x02013;<lpage>601</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000890</pub-id><?supplied-pmid 20693420?><pub-id pub-id-type="pmid">20693420</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manca</surname><given-names>C</given-names></name><name><surname>Tsenova</surname><given-names>L</given-names></name><name><surname>Bergtold</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Tovey</surname><given-names>M</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Virulence of a <italic>Mycobacterium tuberculosis</italic> clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2001</year>) <volume>98</volume>:<fpage>5752</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.091096998</pub-id><?supplied-pmid 11320211?><pub-id pub-id-type="pmid">11320211</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reutterer</surname><given-names>B</given-names></name><name><surname>Stockinger</surname><given-names>S</given-names></name><name><surname>Pilz</surname><given-names>A</given-names></name><name><surname>Soulat</surname><given-names>D</given-names></name><name><surname>Kastner</surname><given-names>R</given-names></name><name><surname>Westermayer</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Type I IFN are host modulators of strain-specific <italic>Listeria monocytogenes</italic> virulence</article-title>. <source>Cell Microbiol</source> (<year>2008</year>) <volume>10</volume>:<fpage>1116</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.01114.x</pub-id><?supplied-pmid 18182083?><pub-id pub-id-type="pmid">18182083</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>L</given-names></name><name><surname>Rothfuchs</surname><given-names>A</given-names></name><name><surname>Goncalves</surname><given-names>R</given-names></name><name><surname>Roffe</surname><given-names>E</given-names></name><name><surname>Cheever</surname><given-names>AW</given-names></name><name><surname>Bafica</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Intranasal poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population</article-title>. <source>J Clin Invest</source> (<year>2010</year>) <volume>120</volume>:<fpage>1674</fpage>&#x02013;<lpage>82</lpage><pub-id pub-id-type="doi">10.1172/JCI40817DS1</pub-id><?supplied-pmid 20389020?><pub-id pub-id-type="pmid">20389020</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarini</surname><given-names>AA</given-names></name><name><surname>Recher</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Georgiev</surname><given-names>P</given-names></name><name><surname>Meury</surname><given-names>S</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2006</year>) <volume>103</volume>:<fpage>15535</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607325103</pub-id><?supplied-pmid 17030789?><pub-id pub-id-type="pmid">17030789</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>JG</given-names></name><name><surname>Broder</surname><given-names>KR</given-names></name><name><surname>Murray</surname><given-names>EL</given-names></name><name><surname>Greenberg</surname><given-names>ME</given-names></name><name><surname>Glover</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Influenza-associated deaths among children in the United States, 2003-2004</article-title>. <source>N Engl J Med</source> (<year>2005</year>) <volume>353</volume>:<fpage>2559</fpage>&#x02013;<lpage>67</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051721</pub-id><pub-id pub-id-type="pmid">16354892</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonsen</surname><given-names>L</given-names></name></person-group>
<article-title>The global impact of influenza on morbidity and mortality</article-title>. <source>Vaccine</source> (<year>1999</year>) <volume>17</volume>(<issue>Suppl 1</issue>):<fpage>S3</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00099-7</pub-id><pub-id pub-id-type="pmid">10471173</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morens</surname><given-names>DM</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group>
<article-title>Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness</article-title>. <source>J Infect Dis</source> (<year>2008</year>) <volume>198</volume>:<fpage>962</fpage>&#x02013;<lpage>70</lpage><pub-id pub-id-type="doi">10.1086/591708</pub-id><pub-id pub-id-type="pmid">18710327</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahangian</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>EK</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>JR</given-names></name><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><etal/></person-group>
<article-title>Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice</article-title>. <source>J Clin Invest</source> (<year>2009</year>) <volume>119</volume>:<fpage>1910</fpage>&#x02013;<lpage>20</lpage><pub-id pub-id-type="doi">10.1172/JCI35412.1910</pub-id><?supplied-pmid 19487810?><pub-id pub-id-type="pmid">19487810</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>CL</given-names></name><name><surname>Al-Bedwawi</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Garber</surname><given-names>G</given-names></name></person-group>
<article-title>Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia</article-title>. <source>Clin Infect Dis</source> (<year>2006</year>) <volume>42</volume>:<fpage>1674</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.1086/504386</pub-id><?supplied-pmid 16705570?><pub-id pub-id-type="pmid">16705570</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J-F</given-names></name><name><surname>Hsieh</surname><given-names>M-Y</given-names></name><name><surname>Hou</surname><given-names>N-J</given-names></name><name><surname>Dai</surname><given-names>C-Y</given-names></name><name><surname>Huang</surname><given-names>J-F</given-names></name><name><surname>Lin</surname><given-names>Z-Y</given-names></name><etal/></person-group>
<article-title>Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice</article-title>. <source>Aliment Pharmacol Ther</source> (<year>2009</year>) <volume>29</volume>:<fpage>1000</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2009.03957.x</pub-id><?supplied-pmid 19210290?><pub-id pub-id-type="pmid">19210290</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roomer</surname><given-names>R</given-names></name><name><surname>Hansen</surname><given-names>BE</given-names></name><name><surname>Janssen</surname><given-names>HLA</given-names></name><name><surname>de Knegt</surname><given-names>RJ</given-names></name></person-group>
<article-title>Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C</article-title>. <source>Hepatology</source> (<year>2010</year>) <volume>52</volume>:<fpage>1225</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="doi">10.1002/hep.23842</pub-id><?supplied-pmid 20830784?><pub-id pub-id-type="pmid">20830784</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MPR</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SAA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title>. <source>Nature</source> (<year>2010</year>) <volume>466</volume>:<fpage>973</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id><pub-id pub-id-type="pmid">20725040</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teles</surname><given-names>RMB</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><name><surname>Montoya</surname><given-names>D</given-names></name><name><surname>Schenk</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses</article-title>. <source>Science</source> (<year>2013</year>) <volume>339</volume>:<fpage>1448</fpage>&#x02013;<lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.1233665</pub-id><?supplied-pmid 23449998?><pub-id pub-id-type="pmid">23449998</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrero</surname><given-names>JA</given-names></name><name><surname>Calderon</surname><given-names>B</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group>
<article-title>Lymphocytes are detrimental during the early innate immune response against <italic>Listeria monocytogenes</italic></article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>:<fpage>933</fpage>&#x02013;<lpage>40</lpage><pub-id pub-id-type="doi">10.1084/jem.20060045</pub-id><?supplied-pmid 16549598?><pub-id pub-id-type="pmid">16549598</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmerling</surname><given-names>P</given-names></name><name><surname>Finger</surname><given-names>H</given-names></name><name><surname>Bockem&#x000fc;hl</surname><given-names>J</given-names></name></person-group>
<article-title><italic>Listeria monocytogenes</italic> infection in nude mice</article-title>. <source>Infect Immun</source> (<year>1975</year>) <volume>12</volume>:<fpage>437</fpage>&#x02013;<lpage>9</lpage><?supplied-pmid 807526?><pub-id pub-id-type="pmid">807526</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Mieno</surname><given-names>M</given-names></name><name><surname>Udono</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Roles of CD4+ and CD8+ cells, and the effect of administration of recombinant murine interferon gamma in listerial infection</article-title>. <source>J Exp Med</source> (<year>1990</year>) <volume>171</volume>:<fpage>1141</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1084/jem.171.4.1141</pub-id><?supplied-pmid 2109036?><pub-id pub-id-type="pmid">2109036</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickol</surname><given-names>AD</given-names></name><name><surname>Bonventre</surname><given-names>PF</given-names></name></person-group>
<article-title>Anomalous high native resistance to athymic mice to bacterial pathogens</article-title>. <source>Infect Immun</source> (<year>1977</year>) <volume>18</volume>:<fpage>636</fpage>&#x02013;<lpage>45</lpage><?supplied-pmid 412787?><pub-id pub-id-type="pmid">412787</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S-J</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name></person-group>
<article-title>Reduced apoptosis and ameliorated listeriosis in TRAIL-null mice</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>:<fpage>5652</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.9.5652</pub-id><?supplied-pmid 15494516?><pub-id pub-id-type="pmid">15494516</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cousens</surname><given-names>L</given-names></name><name><surname>Orange</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Biron</surname><given-names>C</given-names></name></person-group>
<article-title>Interferon-a/b inhibition of interleukin 12 and interferon-g production in vitro and endogenously during viral infection</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1997</year>) <volume>94</volume>:<fpage>634</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.2.634</pub-id><?supplied-pmid 9012836?><pub-id pub-id-type="pmid">9012836</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarda</surname><given-names>G</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name><name><surname>Staehli</surname><given-names>F</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Mattmann</surname><given-names>C</given-names></name><name><surname>F&#x000f6;rster</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Type I interferon inhibits interleukin-1 production and inflammasome activation</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>213</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.02.006</pub-id><?supplied-pmid 21349431?><pub-id pub-id-type="pmid">21349431</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Shenderov</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>SD</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name><name><surname>Cheever</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Caspase-1 independent IL-1beta production is critical for host resistance to <italic>Mycobacterium tuberculosis</italic> and does not require TLR signaling in vivo</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<fpage>3326</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0904189</pub-id><?supplied-pmid 20200276?><pub-id pub-id-type="pmid">20200276</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novikov</surname><given-names>A</given-names></name><name><surname>Cardone</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>R</given-names></name><name><surname>Shenderov</surname><given-names>K</given-names></name><name><surname>Kirschman</surname><given-names>KD</given-names></name><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><etal/></person-group>
<article-title><italic>Mycobacterium tuberculosis</italic> triggers host type I IFN signaling to regulate IL-1&#x003b2; production in human macrophages</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<fpage>2540</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100926</pub-id><?supplied-pmid 21784976?><pub-id pub-id-type="pmid">21784976</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzoza-Lewis</surname><given-names>KL</given-names></name><name><surname>Hoth</surname><given-names>JJ</given-names></name><name><surname>Hiltbold</surname><given-names>EM</given-names></name></person-group>
<article-title>Type I interferon signaling regulates the composition of inflammatory infiltrates upon infection with <italic>Listeria monocytogenes</italic></article-title>. <source>Cell Immunol</source> (<year>2012</year>) <volume>273</volume>:<fpage>41</fpage>&#x02013;<lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2011.11.008</pub-id><?supplied-pmid 22212606?><pub-id pub-id-type="pmid">22212606</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>KM</given-names></name><name><surname>Weiser</surname><given-names>JN</given-names></name></person-group>
<article-title>Synergistic stimulation of type I interferons during influenza virus coinfection promotes <italic>Streptococcus pneumoniae</italic> colonization in mice</article-title>. <source>J Clin Invest</source> (<year>2011</year>) <volume>121</volume>:<fpage>3657</fpage>&#x02013;<lpage>65</lpage><pub-id pub-id-type="doi">10.1172/JCI57762.of</pub-id><?supplied-pmid 21841308?><pub-id pub-id-type="pmid">21841308</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serbina</surname><given-names>NV</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group>
<article-title>Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2</article-title>. <source>Nat Immunol</source> (<year>2006</year>) <volume>7</volume>:<fpage>311</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ni1309</pub-id><pub-id pub-id-type="pmid">16462739</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurihara</surname><given-names>T</given-names></name><name><surname>Warr</surname><given-names>G</given-names></name><name><surname>Loy</surname><given-names>J</given-names></name><name><surname>Bravo</surname><given-names>R</given-names></name></person-group>
<article-title>Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor</article-title>. <source>J Exp Med</source> (<year>1997</year>) <volume>186</volume>:<fpage>1757</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="doi">10.1084/jem.186.10.1757</pub-id><?supplied-pmid 9362535?><pub-id pub-id-type="pmid">9362535</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serbina</surname><given-names>NV</given-names></name><name><surname>Jia</surname><given-names>T</given-names></name><name><surname>Hohl</surname><given-names>TM</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group>
<article-title>Monocyte-mediated defense against microbial pathogens</article-title>. <source>Annu Rev Immunol</source> (<year>2008</year>) <volume>26</volume>:<fpage>421</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090326</pub-id><?supplied-pmid 18303997?><pub-id pub-id-type="pmid">18303997</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>KD</given-names></name><name><surname>Sieve</surname><given-names>AN</given-names></name><name><surname>Indramohan</surname><given-names>M</given-names></name><name><surname>Break</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>RE</given-names></name></person-group>
<article-title>Specific depletion reveals a novel role for neutrophil-mediated protection in the liver during <italic>Listeria monocytogenes</italic> infection</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>:<fpage>2666</fpage>&#x02013;<lpage>76</lpage><pub-id pub-id-type="doi">10.1002/eji.201041363</pub-id><?supplied-pmid 21660934?><pub-id pub-id-type="pmid">21660934</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Hohl</surname><given-names>TM</given-names></name><name><surname>Leiner</surname><given-names>I</given-names></name><name><surname>Equinda</surname><given-names>MJ</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group>
<article-title>Ly6G+ neutrophils are dispensable for defense against systemic <italic>Listeria monocytogenes</italic> infection</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<fpage>5293</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101721</pub-id><?supplied-pmid 21976773?><pub-id pub-id-type="pmid">21976773</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lykens</surname><given-names>JE</given-names></name><name><surname>Terrell</surname><given-names>CE</given-names></name><name><surname>Zoller</surname><given-names>EE</given-names></name><name><surname>Divanovic</surname><given-names>S</given-names></name><name><surname>Trompette</surname><given-names>A</given-names></name><name><surname>Karp</surname><given-names>CL</given-names></name><etal/></person-group>
<article-title>Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivo</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>:<fpage>877</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902346</pub-id><?supplied-pmid 20018611?><pub-id pub-id-type="pmid">20018611</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Waldburger</surname><given-names>J-M</given-names></name></person-group>
<article-title>Regulation of MHC class II gene expression by the class II transactivator</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>:<fpage>793</fpage>&#x02013;<lpage>806</lpage><pub-id pub-id-type="doi">10.1038/nri1708</pub-id><?supplied-pmid 16200082?><pub-id pub-id-type="pmid">16200082</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>EB</given-names></name><name><surname>Yamada</surname><given-names>DH</given-names></name><name><surname>Elsaesser</surname><given-names>H</given-names></name><name><surname>Herskovitz</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Blockade of chronic type I interferon signaling to control persistent LCMV infection</article-title>. <source>Science</source> (<year>2013</year>) <volume>340</volume>:<fpage>202</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="doi">10.1126/science.1235208</pub-id><?supplied-pmid 23580528?><pub-id pub-id-type="pmid">23580528</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Sullivan</surname><given-names>BM</given-names></name><name><surname>Sheehan</surname><given-names>KCF</given-names></name><name><surname>Welch</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Persistent LCMV infection is controlled by blockade of type I interferon signaling</article-title>. <source>Science</source> (<year>2013</year>) <volume>340</volume>:<fpage>207</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="doi">10.1126/science.1235214</pub-id><?supplied-pmid 23580529?><pub-id pub-id-type="pmid">23580529</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Jaiswal</surname><given-names>A</given-names></name><name><surname>Arora</surname><given-names>VK</given-names></name><name><surname>Prasad</surname><given-names>HK</given-names></name></person-group>
<article-title>Modulation of gamma interferon receptor 1 by <italic>Mycobacterium tuberculosis</italic>: a potential immune response evasive mechanism</article-title>. <source>Infect Immun</source> (<year>2007</year>) <volume>75</volume>:<fpage>2500</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="doi">10.1128/IAI.01743-06</pub-id><?supplied-pmid 17339358?><pub-id pub-id-type="pmid">17339358</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>SJ</given-names></name><name><surname>Delgado</surname><given-names>C</given-names></name><name><surname>Eshleman</surname><given-names>EM</given-names></name><name><surname>Hill</surname><given-names>KK</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>BP</given-names></name><name><surname>Lenz</surname><given-names>LL</given-names></name></person-group>
<article-title>Type I IFNs downregulate myeloid cell IFN-&#x003b3; receptor by inducing recruitment of an early growth response 3/NGFI-A binding protein 1 complex that silences ifngr1 transcription</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>:<fpage>3384</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1203510</pub-id><?supplied-pmid 23935197?><pub-id pub-id-type="pmid">23935197</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>KM</given-names></name><name><surname>Gunn</surname><given-names>JS</given-names></name><name><surname>Lafuse</surname><given-names>W</given-names></name><name><surname>Satoskar</surname><given-names>AR</given-names></name></person-group>
<article-title><italic>Francisella</italic> inhibits STAT1-mediated signaling in macrophages and prevents activation of antigen-specific T cells</article-title>. <source>Int Immunol</source> (<year>2009</year>) <volume>21</volume>:<fpage>19</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxn119</pub-id><?supplied-pmid 19001470?><pub-id pub-id-type="pmid">19001470</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donovan</surname><given-names>KJ</given-names></name><name><surname>Tourtellotte</surname><given-names>WG</given-names></name><name><surname>Millbrandt</surname><given-names>J</given-names></name><name><surname>Baraban</surname><given-names>JM</given-names></name></person-group>
<article-title>The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience</article-title>. <source>Trends Neurosci</source> (<year>1999</year>) <volume>22</volume>:<fpage>167</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(98)01343-5</pub-id><?supplied-pmid 10203854?><pub-id pub-id-type="pmid">10203854</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swirnoff</surname><given-names>A</given-names></name><name><surname>Milbrandt</surname><given-names>J</given-names></name></person-group>
<article-title>DNA-binding specificity of NGFI-A and related zinc finger transcription factors</article-title>. <source>Mol Cell Biol</source> (<year>1995</year>) <volume>15</volume>:<fpage>2275</fpage>&#x02013;<lpage>87</lpage><?supplied-pmid 7891721?><pub-id pub-id-type="pmid">7891721</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>de Belle</surname><given-names>I</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Adamson</surname><given-names>ED</given-names></name></person-group>
<article-title>Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses</article-title>. <source>Mol Cell</source> (<year>2004</year>) <volume>15</volume>:<fpage>83</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.06.030</pub-id><?supplied-pmid 15225550?><pub-id pub-id-type="pmid">15225550</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RP</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>deBelle</surname><given-names>I</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Matheny</surname><given-names>W</given-names></name><name><surname>Adamson</surname><given-names>ED</given-names></name></person-group>
<article-title>Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation</article-title>. <source>Cell Death Differ</source> (<year>1998</year>) <volume>5</volume>:<fpage>96</fpage>&#x02013;<lpage>106</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400322</pub-id><?supplied-pmid 10200450?><pub-id pub-id-type="pmid">10200450</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>KM</given-names></name><name><surname>Stewart</surname><given-names>SE</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Woodman</surname><given-names>CBJ</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>JD</given-names></name><name><surname>Dawson</surname><given-names>CW</given-names></name><etal/></person-group>
<article-title>The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation</article-title>. <source>Oncogene</source> (<year>2009</year>) <volume>28</volume>:<fpage>3903</fpage>&#x02013;<lpage>14</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.249</pub-id><?supplied-pmid 19718044?><pub-id pub-id-type="pmid">19718044</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Thai</surname><given-names>V</given-names></name><name><surname>McCabe</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Macnamara</surname><given-names>KC</given-names></name></person-group>
<article-title>Type I interferons promote severe disease in a mouse model of lethal ehrlichiosis</article-title>. <source>Infect Immun</source> (<year>2014</year>) <volume>82</volume>:<fpage>1698</fpage>&#x02013;<lpage>709</lpage><pub-id pub-id-type="doi">10.1128/IAI.01564-13</pub-id><?supplied-pmid 24491580?><pub-id pub-id-type="pmid">24491580</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernbauer</surname><given-names>E</given-names></name><name><surname>Maier</surname><given-names>V</given-names></name><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name></person-group>
<article-title>Route of infection determines the impact of type I interferons on innate immunity to <italic>Listeria monocytogenes</italic></article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e65007</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0065007</pub-id><?supplied-pmid 23840314?><pub-id pub-id-type="pmid">23840314</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baechler</surname><given-names>EC</given-names></name><name><surname>Batliwalla</surname><given-names>FM</given-names></name><name><surname>Karypis</surname><given-names>G</given-names></name><name><surname>Gaffney</surname><given-names>PM</given-names></name><name><surname>Ortmann</surname><given-names>WA</given-names></name><name><surname>Espe</surname><given-names>KJ</given-names></name><etal/></person-group>
<article-title>Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>:<fpage>2610</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.0337679100</pub-id><?supplied-pmid 12604793?><pub-id pub-id-type="pmid">12604793</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirou</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Louca</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>MGE</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name></person-group>
<article-title>Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease</article-title>. <source>Arthritis Rheum</source> (<year>2005</year>) <volume>52</volume>:<fpage>1491</fpage>&#x02013;<lpage>503</lpage><pub-id pub-id-type="doi">10.1002/art.21031</pub-id><pub-id pub-id-type="pmid">15880830</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>L</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Arce</surname><given-names>E</given-names></name><name><surname>Cantrell</surname><given-names>V</given-names></name><name><surname>Borvak</surname><given-names>J</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Interferon and granulopoiesis signatures in systemic lupus erythematosus blood</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>197</volume>:<fpage>711</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="doi">10.1084/jem.20021553</pub-id><?supplied-pmid 12642603?><pub-id pub-id-type="pmid">12642603</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JC</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name></person-group>
<article-title>Type I interferons: crucial participants in disease amplification in autoimmunity</article-title>. <source>Nat Rev Rheumatol</source> (<year>2010</year>) <volume>6</volume>:<fpage>40</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2009.237</pub-id><?supplied-pmid 20046205?><pub-id pub-id-type="pmid">20046205</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Vukusic</surname><given-names>S</given-names></name><name><surname>Gignoux</surname><given-names>L</given-names></name><name><surname>Dubief</surname><given-names>FD</given-names></name><name><surname>Achiti</surname><given-names>I</given-names></name><name><surname>Blanc</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of responders to interferon therapy for relapsing MS</article-title>. <source>Neurology</source> (<year>2003</year>) <volume>61</volume>:<fpage>184</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000078888.07196.0B</pub-id><?supplied-pmid 12874396?><pub-id pub-id-type="pmid">12874396</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teige</surname><given-names>I</given-names></name><name><surname>Treschow</surname><given-names>A</given-names></name><name><surname>Teige</surname><given-names>A</given-names></name><name><surname>Mattsson</surname><given-names>R</given-names></name><name><surname>Navikas</surname><given-names>V</given-names></name><name><surname>Leanderson</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>IFN-B gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>170</volume>:<fpage>4776</fpage>&#x02013;<lpage>84</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.9.4776</pub-id><?supplied-pmid 12707359?><pub-id pub-id-type="pmid">12707359</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Knobeloch</surname><given-names>K-P</given-names></name><name><surname>Hanisch</surname><given-names>U-K</given-names></name><name><surname>Raasch</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>28</volume>:<fpage>675</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.011</pub-id><?supplied-pmid 18424188?><pub-id pub-id-type="pmid">18424188</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>B</given-names></name><name><surname>Kraan</surname><given-names>M</given-names></name></person-group>
<article-title>The effects of interferon beta treatment on arthritis</article-title>. <source>Rheumatology</source> (<year>1999</year>) <volume>38</volume>:<fpage>362</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/38.4.362</pub-id><pub-id pub-id-type="pmid">10378715</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>F</given-names></name><name><surname>Chalise</surname><given-names>JP</given-names></name><name><surname>Narendra</surname><given-names>SC</given-names></name><name><surname>Magnusson</surname><given-names>M</given-names></name></person-group>
<article-title>Type I IFN protects against antigen-induced arthritis</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>:<fpage>1687</fpage>&#x02013;<lpage>95</lpage><pub-id pub-id-type="doi">10.1002/eji.201040956</pub-id><?supplied-pmid 21469099?><pub-id pub-id-type="pmid">21469099</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>G</given-names></name><name><surname>Foster</surname><given-names>J</given-names></name><name><surname>Vessillier</surname><given-names>S</given-names></name><name><surname>K&#x000f6;ster</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints</article-title>. <source>Ann Rheum Dis</source> (<year>2013</year>) <volume>73</volume>(<issue>9</issue>):<fpage>1728</fpage>&#x02013;<lpage>36</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203513</pub-id><?supplied-pmid 23813971?><pub-id pub-id-type="pmid">23813971</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>I</given-names></name><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>
<article-title>Protein tyrosine phosphatases in lymphocyte activation and autoimmunity</article-title>. <source>Nat Immunol</source> (<year>2012</year>) <volume>13</volume>:<fpage>439</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="doi">10.1038/ni.2246</pub-id><?supplied-pmid 22513334?><pub-id pub-id-type="pmid">22513334</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shaked</surname><given-names>I</given-names></name><name><surname>Stanford</surname><given-names>SM</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Curtsinger</surname><given-names>JM</given-names></name><name><surname>Mikulski</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>39</volume>:<fpage>111</fpage>&#x02013;<lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.013</pub-id><?supplied-pmid 23871208?><pub-id pub-id-type="pmid">23871208</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Rachmilewitz</surname><given-names>D</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name></person-group>
<article-title>Homeostatic effects of TLR9 signaling in experimental colitis</article-title>. <source>Ann N Y Acad Sci</source> (<year>2006</year>) <volume>1072</volume>:<fpage>351</fpage>&#x02013;<lpage>5</lpage><pub-id pub-id-type="doi">10.1196/annals.1326.022</pub-id><?supplied-pmid 17057215?><pub-id pub-id-type="pmid">17057215</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannon</surname><given-names>PJ</given-names></name><name><surname>Hornung</surname><given-names>RL</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Groden</surname><given-names>C</given-names></name><name><surname>Friend</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Suppression of inflammation in ulcerative colitis by interferon-&#x003b2;-1a is accompanied by inhibition of IL-13 production</article-title>. <source>Gut</source> (<year>2011</year>) <volume>60</volume>:<fpage>449</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="doi">10.1136/gut.2010.226860</pub-id><?supplied-pmid 20971977?><pub-id pub-id-type="pmid">20971977</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaus</surname><given-names>S</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Fedorak</surname><given-names>R</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Wild</surname><given-names>GE</given-names></name><name><surname>Theuer</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study</article-title>. <source>Gut</source> (<year>2003</year>) <volume>52</volume>:<fpage>1286</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="doi">10.1136/gut.52.9.1286</pub-id><?supplied-pmid 12912859?><pub-id pub-id-type="pmid">12912859</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>I</given-names></name><name><surname>Hainzl</surname><given-names>E</given-names></name><name><surname>Rosebrock</surname><given-names>F</given-names></name><name><surname>Heider</surname><given-names>S</given-names></name><name><surname>Schwab</surname><given-names>C</given-names></name><name><surname>Stoiber</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Type I interferons have opposing effects during the emergence and recovery phases of colitis</article-title>. <source>Eur J Cancer</source> (<year>2014</year>).<pub-id pub-id-type="doi">10.1002/eji.201344401</pub-id><?supplied-pmid 24975266?><pub-id pub-id-type="pmid">24975266</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katakura</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Rachmilewitz</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Eckmann</surname><given-names>L</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name></person-group>
<article-title>Toll-like receptor 9 &#x02013; induced type I IFN protects mice from experimental colitis</article-title>. <source>J Clin Invest</source> (<year>2005</year>) <volume>115</volume>:<fpage>695</fpage>&#x02013;<lpage>702</lpage><pub-id pub-id-type="doi">10.1172/JCI200522996DS1</pub-id><?supplied-pmid 15765149?><pub-id pub-id-type="pmid">15765149</pub-id></mixed-citation></ref></ref-list></back></article>